[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 182
1. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP, Skak K, Lundsgaard D, Frederiksen KS, Thygesen P, McArthur GA: An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res; 2007 Jun 15;13(12):3630-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
  • We report a phase 1 study of recombinant human IL-21 in patients with surgically incurable metastatic melanoma.
  • EXPERIMENTAL DESIGN: Open-label, two-arm, dose escalation trial of IL-21 administered by i.v. bolus injection at dose levels from 1 to 100 microg/kg using two parallel treatment regimens: thrice weekly for 6 weeks (3/wk) or three cycles of daily dosing for 5 days followed by 9 days of rest (5+9).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interleukins / administration & dosage. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575227.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Interleukins; 0 / Pore Forming Cytotoxic Proteins; 0 / Recombinant Proteins; 0 / interleukin-21; 126465-35-8 / Perforin; EC 3.4.21.- / Granzymes
  •  go-up   go-down


2. Conway C, Beswick S, Elliott F, Chang YM, Randerson-Moor J, Harland M, Affleck P, Marsden J, Sanders DS, Boon A, Knowles MA, Bishop DT, Newton-Bishop JA: Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer; 2010 May;49(5):425-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.
  • We report an investigation of gene dosage at 9p21.3 and mutations in BRAF and NRAS, as predictors of relapse and histological markers of poor melanoma prognosis.
  • This study presents supportive evidence that CDKN2B, P14ARF, and CDKN2A may all play a tumor suppressor role in melanoma progression.
  • [MeSH-major] Chromosomes, Human, Pair 9. Gene Deletion. Genes, ras. Melanoma / genetics. Proto-Oncogene Proteins B-raf / genetics

  • Genetic Alliance. consumer health - Chromosome 9, Monosomy 9p.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] Oncogene. 2003 Dec 18;22(58):9217-24 [14681681.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):22-30 [10072356.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):331-5 [14719109.001]
  • [Cites] Cancer Lett. 2004 Oct 28;214(2):133-47 [15363539.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):23-6 [7987388.001]
  • [Cites] Oncogene. 1999 Apr 15;18(15):2527-32 [10229204.001]
  • [Cites] Melanoma Res. 1999 Feb;9(1):10-9 [10338330.001]
  • [Cites] Arch Dermatol Res. 1999 Jul-Aug;291(7-8):474-7 [10482020.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5311-7 [10498883.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):9-16 [15714058.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2991-7 [15837753.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Nucleic Acids Res. 2005;33(14):e128 [16106041.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8065-75 [16258105.001]
  • [Cites] Melanoma Res. 2006 Aug;16(4):267-73 [16845322.001]
  • [Cites] Melanoma Res. 2006 Dec;16(6):471-8 [17119447.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Feb;133(2):117-23 [16977458.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3963-9 [17440112.001]
  • [Cites] J Dtsch Dermatol Ges. 2007 Jun;5(6):456-9 [17537037.001]
  • [Cites] Nature. 2007 Aug 23;448(7156):943-6 [17713536.001]
  • [Cites] Methods Mol Biol. 2008;439:101-8 [18370098.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 6;370(3):509-13 [18402768.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):784-95 [18505964.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):757-9 [18505965.001]
  • [Cites] Cell Cycle. 2008 Jul 1;7(13):1944-8 [18604170.001]
  • [Cites] Eur J Cancer. 2008 Aug;44(12):1717-25 [18602256.001]
  • [Cites] PLoS One. 2009;4(4):e5027 [19343170.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):395-405 [19383313.001]
  • [Cites] J Invest Dermatol. 2009 Jun;129(6):1483-8 [19037234.001]
  • [Cites] Pigment Cell Melanoma Res. 2009 Aug;22(4):445-53 [19368689.001]
  • [Cites] Virchows Arch. 2009 Sep;455(3):213-23 [19697059.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1671-7 [19592466.001]
  • [Cites] Clin Cancer Res. 2009 Nov 15;15(22):6939-46 [19887478.001]
  • [Cites] Nat Cell Biol. 1999 May;1(1):20-6 [10559859.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3511-5 [10999737.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Arch Dermatol. 2001 Nov;137(11):1493-6 [11708953.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12):e57 [12060695.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):894-903 [12072543.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):229-37 [12107107.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):675-82 [12296515.001]
  • [Cites] Melanoma Res. 2002 Dec;12(6):539-47 [12459643.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):683-90 [12875987.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1083-90 [8640765.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):5023-32 [8895759.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):255-9 [9221801.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5336-47 [9393758.001]
  • [Cites] Int J Cancer. 1998 May 4;76(3):312-6 [9579564.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):157-63 [9598804.001]
  • [Cites] J Cutan Pathol. 1998 Jul;25(6):291-6 [9694617.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6483-8 [14695152.001]
  • (PMID = 20140953.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p14ARF; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 2.4.2.28 / 5'-methylthioadenosine phosphorylase; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC2948432
  •  go-up   go-down


3. Eggermont AM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, Gogas H, MacKie RM, Hauschild A: Utility of adjuvant systemic therapy in melanoma. Ann Oncol; 2009 Aug;20 Suppl 6:vi30-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of adjuvant systemic therapy in melanoma.
  • The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III disease.
  • Observation is still an appropriate control arm in adjuvant clinical trials.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2444-58 [10856105.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):841-6 [20048184.001]
  • [Cites] Lancet. 2001 Sep 15;358(9285):866-9 [11567700.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(17):2147-53 [11677100.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1818-25 [11919239.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2058-66 [11956266.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2067-75 [11956267.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4181-90 [12377961.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4549-54 [12454111.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2883-8 [12885805.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):241-52 [12927565.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):53-61 [14665609.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1670-7 [15014018.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1036-44 [8164027.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1425-9 [9552047.001]
  • [Cites] Lancet. 1998 Jun 27;351(9120):1905-10 [9654256.001]
  • [Cites] Lancet. 2005 Oct 1;366(9492):1189-96 [16198768.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8655-63 [16260701.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2078-85 [17513813.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):509-15 [18083374.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1195-201 [18281266.001]
  • [Cites] Lancet. 2008 Jul 12;372(9633):117-26 [18620949.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):939-44 [19139440.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1146-9 [11379605.001]
  • (PMID = 19617295.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC2712588
  •  go-up   go-down


Advertisement
4. Tarhini AA, Kirkwood JM, Tawbi H, Gooding WE, Islam MF, Agarwala SS: Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer; 2008 Mar 1;112(5):1131-8
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma.
  • BACKGROUND: Arsenic trioxide (ATO) cytotoxicity and apoptosis induction has been demonstrated with numerous cancer cell lines, including human melanoma.
  • METHODS: A second-line, phase 2, single-arm study of ATO was conducted in patients with inoperable American Joint Committee on Cancer (AJCC) stage IV melanoma.
  • All had stage IV melanoma including M1a (2 patients), M1b (6 patients), and M1c (13 patients) disease.
  • One patient had metastatic choroidal melanoma and 20 patients had cutaneous melanoma.
  • CONCLUSIONS: ATO as tested in the current trial was found to be well tolerated and had limited activity in patients with metastatic melanoma.
  • The application of this agent in combination with either chemotherapy or agents that target recognized critical signaling and antiapoptotic pathways of melanoma has not yet been performed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Arsenicals / therapeutic use. Choroid Neoplasms / drug therapy. Melanoma / drug therapy. Oxides / therapeutic use. Oxides / toxicity. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer. 2013 Feb 15;119(4):924
  • (PMID = 18286511.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA121973
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


5. Mowbray M, Stockton DL, Doherty VR: Changes in the site distribution of malignant melanoma in South East Scotland (1979-2002). Br J Cancer; 2007 Mar 12;96(5):832-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the site distribution of malignant melanoma in South East Scotland (1979-2002).
  • Scottish Melanoma Group (SMG) data on 2790 melanoma (MM) cases in South East Scotland over a 24-year time period were analysed in four periods each of 6 years duration grouped into frequently exposed, intermittently exposed, and always covered sites.
  • In both sexes, the proportion of cases seen on the posterior trunk and arm increased significantly (P<0.001), but declines were seen in the proportion of leg tumours in males (P=0.09) and of head tumours in females (P=0.011).
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):380-4 [16477634.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):627-32 [10699940.001]
  • [Cites] Int J Epidemiol. 2000 Jun;29(3):416-23 [10869312.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):457-62 [11291086.001]
  • [Cites] Lancet. 2002 Aug 24;360(9333):587-91 [12241928.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):45-60 [15617990.001]
  • [Cites] Int J Cancer. 1991 Feb 20;47(4):483-9 [1995477.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):232-6 [8425760.001]
  • [Cites] Cancer Causes Control. 1994 Jul;5(4):341-50 [8080946.001]
  • [Cites] Health Rep. 1998 Autumn;10(2):29-41 (Eng); 33-46 (Fre) [9842489.001]
  • [Cites] Cancer Causes Control. 1999 Oct;10(5):407-16 [10530611.001]
  • [Cites] Am J Epidemiol. 1990 Dec;132(6):1066-77 [2260538.001]
  • (PMID = 17299392.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360061
  •  go-up   go-down


6. Frenkel S, Barzel I, Levy J, Lin AY, Bartsch DU, Majumdar D, Folberg R, Pe'er J: Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography. Eye (Lond); 2008 Jul;22(7):948-52
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography.
  • PURPOSE: Vasculogenic mimicry patterns, formed by highly invasive melanoma cells, connect to endothelial cell-lined blood vessels and contain fluid in vitroand in vivo.
  • METHODS: Indocyanine green (ICG) laser scanning confocal angiography (Heidelberg Retinal Angiograph (HRA); Heidelberg Engineering, Heidelberg, Germany) was performed on nine patients with posterior choroidal melanoma in an institutional setting.
  • Blood was drawn before the ICG injection and from the contralateral arm of the ICG injection site and 1 min after the injection.

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Arch Ophthalmol. 1998 Apr;116(4):455-63 [9565042.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jul;129(7):884-92 [15974811.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3013-20 [16123395.001]
  • [Cites] Am J Ophthalmol. 2005 Oct;140(4):748-9 [16226537.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2471-80 [10509639.001]
  • [Cites] Ophthalmology. 1998 Mar;105(3):485-91 [9499780.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):383-8 [10666365.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1422-8 [11381041.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):113-9 [17536318.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Apr;43(4):912-8 [11923228.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2533-9 [12147581.001]
  • [Cites] Lab Invest. 2002 Aug;82(8):1031-43 [12177242.001]
  • [Cites] Ophthalmology. 2002 Dec;109(12):2207-14 [12466160.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1008-11 [12601021.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2965-70 [12782604.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2834-40 [12824220.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2003 Nov;25(6):524-6 [14690552.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1389-98 [8371929.001]
  • [Cites] Am J Ophthalmol. 1996 Mar;121(3):276-83 [8597270.001]
  • [Cites] Lancet. 1996 May 4;347(9010):1222-5 [8622452.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1203-17 [8644861.001]
  • [Cites] Lab Invest. 1996 Jul;75(1):55-66 [8683940.001]
  • [Cites] Ophthalmology. 1997 May;104(5):777-80 [9160022.001]
  • [Cites] Arch Ophthalmol. 1998 Jan;116(1):31-9 [9445206.001]
  • (PMID = 17363922.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / EY 016323; United States / NEI NIH HHS / EY / R01 EY010457; United States / NEI NIH HHS / EY / R01 EY010457-12; United States / NEI NIH HHS / EY / R01 EY016323; United States / NEI NIH HHS / EY / EY010457-12; United States / NEI NIH HHS / EY / EY 10457
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] IX6J1063HV / Indocyanine Green
  • [Other-IDs] NLM/ NIHMS15384; NLM/ PMC2551555
  •  go-up   go-down


7. Guo J, Zhu J, Sheng X, Wang X, Qu L, Han Y, Liu Y, Zhang H, Huo L, Zhang S, Lin B, Yang Z: Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer; 2007 Jun 1;120(11):2418-25
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma.
  • In this study, we determine if intratumoral injection of immature DC after LHT (LHT+IT-DC) induces systemic antitumor immunity in patients with advanced melanoma, and investigate the potential immunological mechanisms involved in the treatments.
  • Patients were randomly assigned to intratumoral administration of autologous immature DC triweekly, with (LHT+IT-DC, arm A, n = 9) or without (IT-DC, arm B, n = 9) LHT.
  • The time to progress (TTP) of arm A was 5 months, significantly longer than that in arm B (2 months, p < 0.05).
  • Our ELISPOT assay showed a significantly increased melanoma-specific IFN-gamma production in arm A, suggesting that LHT+IT-DC was more effective in the induction of cytotoxic T lymphocytes (CTL) than IT-DC alone.
  • Furthermore, we detected an increased HSPs expression 4 hr after the first LHT, an enhanced Th1/Th2 chemokines production 24 hr after the first LHT+IT-DC treatment, a promoted migration of DC to afferent lymph nodes, and a decreased infiltration of regulatory T cells (CD4(+)CD25(+)) and an increased infiltration of active CTL (CD8(+)CD28(+)) 48 hr after the third DC injection in arm A patients.
  • Therefore, LHT+IT-DC can induce effective specific antitumor immunity and facilitate a Th1-polarized immune response in patients with advanced melanoma.
  • [MeSH-major] Dendritic Cells / transplantation. Hyperthermia, Induced. Melanoma / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294445.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Aguilar García G, Serrano Falcón C, Serrano Falcón Mdel M, Carmona MD, Linares Solano J, Serrano Ortega S: [Cutaneous necrosis due to interferon alpha in a patient with melanoma]. Actas Dermosifiliogr; 2006 Oct;97(8):539-42
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous necrosis due to interferon alpha in a patient with melanoma].
  • [Transliterated title] Necrosis cutánea por interferón alfa en paciente con melanoma.
  • We present the case of a 55-year-old male with melanoma in the right retroauricular region who had cutaneous necrosis only in one of the injection sites after adjuvant treatment with interferon (IFN alpha 2b) according to the Kirkwood proposed regime.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Interferon-alpha / adverse effects. Melanoma / drug therapy. Necrosis / chemically induced. Skin / pathology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Arm. Chemotherapy, Adjuvant. Debridement. Follow-Up Studies. Humans. Injections, Intravenous. Male. Middle Aged. Ointments. Recombinant Proteins. Skin Ulcer / chemically induced. Skin Ulcer / drug therapy. Skin Ulcer / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067536.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ointments; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


9. Sendi P, Puric E, Schönenberger A, Bargetzi M: [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination]. Praxis (Bern 1994); 2007 May 2;96(18):729-32
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
  • [Transliterated title] Chronische lymphatische Leukämie und Kraftverlust im rechten Arm--eine nicht typische Kombination.
  • In addition some forms of tumors, such as Kaposi sarkoma, malignant melanoma, laryngeal carcinoma, lung cancer and Hodgkin Lymphoma are found more frequently in this patient population.
  • [MeSH-minor] Administration, Oral. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arm. Benzenesulfonates / administration & dosage. Benzenesulfonates / therapeutic use. Bone Neoplasms / secondary. Clinical Trials, Phase III as Topic. Disease Progression. Humans. Hypesthesia / etiology. Indoles / administration & dosage. Indoles / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Muscle Weakness / etiology. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / therapeutic use. Pyridines / administration & dosage. Pyridines / therapeutic use. Pyrroles / administration & dosage. Pyrroles / therapeutic use. Radiography, Abdominal. Radiography, Thoracic. Risk. Risk Factors. Sex Factors. Splenic Neoplasms / secondary. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520841.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


10. Fujiwara M, Suzuki A, Mizukami T, Nagata T, Ito T, Fukamizu H: Mid-arm lymph nodes dissection for melanoma. J Plast Reconstr Aesthet Surg; 2010 Sep;63(9):1561-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mid-arm lymph nodes dissection for melanoma.
  • An interval node in the upper limb termed the mid-arm node was recently identified.
  • We report a patient with metastatic melanoma of the mid-arm node and the epitrochlear node at 10 years after removal of the primary tumour from the forearm and therapeutic axillary lymph node dissection.
  • The mid-arm node is located halfway up the upper arm on the medial intermuscular septum, at the site where the brachial vessels, the median nerve and the ulnar nerve run adjacent to each other.
  • The mid-arm node lies adjacent to the basilic vein where lymphatic vessels ascend and converge.
  • This is the first report regarding the surgical anatomy of the mid-arm node.
  • [MeSH-major] Forearm / surgery. Lymphatic Vessels / surgery. Melanoma / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20227935.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Sunderkötter C, Eickelmann M, Köhler M, Schmittel A, Wacker FK: Remission of extensive intrahepatic metastasis by C-arm computed tomography guided chemoembolization in uveal melanoma. J Dtsch Dermatol Ges; 2010 Jul;8(7):525-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of extensive intrahepatic metastasis by C-arm computed tomography guided chemoembolization in uveal melanoma.
  • As soon as uveal melanoma has metastasized to the liver, response rates to systemic chemotherapy are low.
  • We subsequently performed two angiographic C-arm CT-guided, superselective chemoembolizations of the hepatic arteries feeding the tumor, using cisplatin, starch microspheres and ethiodized oil.
  • However, the selective angiographic C-arm CT-guided chemoembolization resulted in prolongation of life with good quality despite the advanced stage of the disease.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Melanoma / secondary. Melanoma / therapy. Radiography, Interventional / methods. Uveal Neoplasms / therapy

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922465.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Kilic E, Naus NC, van Gils W, Klaver CC, van Til ME, Verbiest MM, Stijnen T, Mooy CM, Paridaens D, Beverloo HB, Luyten GP, de Klein A: Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci; 2005 Jul;46(7):2253-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients.
  • PURPOSE: Uveal melanoma is a highly malignant disease with a mortality rate of 50% at 10 to 15 years.
  • In the present study, the independent numerical changes in chromosomes 1, 3, 6, and 8 on disease-free survival (DFS) was assessed in a large series of patients with uveal melanoma.
  • METHODS: One hundred twenty tumors from patients with uveal melanoma were analyzed for numerical changes in chromosomes 1, 3, 6, and 8, with cytogenetic analysis, fluorescent in situ hybridization, and/or comparative genomic hybridization.
  • Regarding all chromosomal changes, only the concurrent loss of the short arm of chromosome 1 and all of chromosome 3 was an independent prognostic parameter for disease-free survival (P < 0.001).
  • CONCLUSIONS: In uveal melanoma, concurrent loss of the short arm of chromosome 1 and all of chromosome 3 is an independent predictor of decreased DFS.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 3 / genetics. Melanoma / genetics. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980208.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. O'Neill PA, Butt M, Eswar CV, Gillis P, Marshall E: A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. Melanoma Res; 2006 Jun;16(3):245-8
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
  • Uveal melanoma is relatively uncommon accounting for fewer than 5% of all melanoma cases.
  • Uncertainty remains concerning the level of activity of dacarbazine in uveal melanoma as opposed to that in the cutaneous form.
  • A phase II study was therefore undertaken to assess the objective response rate of the combination of dacarbazine and treosulfan in previously untreated patients with metastatic uveal melanoma.
  • This study, using the combination of dacarbazine and treosulfan, while well tolerated, did not confirm earlier reports suggesting treosulfan is active in uveal melanoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Uveal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. TREOSULFAN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16718271.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; CO61ER3EPI / treosulfan; G1LN9045DK / Busulfan
  •  go-up   go-down


14. Vukomanovic P, Karanikolic A, Stefanoviic M, Mihajlovic D, Djordjevic B, Kutlesic R: Late recurrence of malignant melanoma mimicking ovarian malignancy. Eur J Gynaecol Oncol; 2010;31(5):590-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence of malignant melanoma mimicking ovarian malignancy.
  • BACKGROUND: Malignant melanoma (MM) is an extremely malignant tumor with an unpredictable profile of spread and variable periods of remission.
  • CASE: We describe an unusual case of malignant melanoma metastatic to the omentum occurring seven years after diagnosis and treatment of cutaneous malignant melanoma in the patient's arm.
  • To date, nine months after detection of malignant melanoma metastatic to the omentum, the patient is alive with no clinical and radiological metastatic disease.
  • CONCLUSIONS: The diagnosis of omentum malignant melanoma in a living patient is uncommon, thus very few individuals and referral centers can build up an adequate experience of handling this disease.
  • [MeSH-major] Melanoma / secondary. Omentum / pathology. Ovarian Neoplasms / ultrasonography. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / ultrasonography. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061811.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. del Boz J, García JM, Martínez S, Gómez M: Giant melanoma and depression. Am J Clin Dermatol; 2009;10(6):419-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant melanoma and depression.
  • A 29-year-old female patient presented with a giant melanoma on the external side of the left arm and concomitant multiple visceral metastases.
  • The patient also had major depression and had avoided a consultation despite the large size of the lesion, delaying the diagnosis and treatment of her melanoma, which as far as we know is the largest, primary cutaneous melanoma ever reported.
  • [MeSH-major] Depressive Disorder / complications. Melanoma / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824743.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


16. Combs D, Baker A, Fu J, Herring A, Jeter J, Cranmer L: Feasibility study of neurocognitive assessment of melanoma patients treated with adjuvant interferon. J Clin Oncol; 2009 May 20;27(15_suppl):e20567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility study of neurocognitive assessment of melanoma patients treated with adjuvant interferon.
  • : e20567 Background: Interferon α-2b (IFN) is the only approved adjuvant therapy for patients diagnosed with high-risk melanoma.
  • METHODS: We enrolled patients with at least stage 2B melanoma who were eligible to receive adjuvant IFN.
  • Controls were those IFN-eligible, but not receiving it or those with unresectable melanoma eligible to receive dacarbazine-based chemotherapy (DTIC).
  • Based on our HVLT data, a total of 17 subjects per arm are required to demonstrate a statistically significant difference (alpha=0.05, beta=0.10).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961131.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA: Effect of granulocyte-macrophage colony stimulating factor (GM-CSF) administered with a multipeptide vaccine on circulating CD8&lt;sup&gt;+&lt;/sup&gt; and CD4&lt;sup&gt;+&lt;/sup&gt; T-cell responses: Outcome of a multicenter randomized trial. J Clin Oncol; 2009 May 20;27(15_suppl):3008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 121 eligible and evaluable patients with resected stage IIB-IV melanoma were administered a sequence of multipeptide vaccines, each consisting of 12 MHC Class I-restricted melanoma peptides (12MP) to stimulate CD8<sup>+</sup> T cells, plus an HLA-DR restricted tetanus helper peptide to stimulate CD4<sup>+</sup> T cells.
  • There have been too few events to assess differences in clinical outcome by study arm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962046.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Saunders M, Anthoney A, Coffey M, Mettinger K, Thompson B, Melcher A, Nutting CM, Harrington K: Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This open-label, single-arm, multicenter Phase 2 study combined ITu reolysin with low-dose fractionated RT.
  • RESULTS: 16 heavily pre-treated pts (9 male, median age 66 yrs, ECOG 0:4pts; 1:12pts) with advanced cancer: melanoma (5), colorectal (4), gastric (1), ovarian (1), pancreas (1), lung (1), cholangiocarcinoma (1), sinus (1), and thyroid (1) were enrolled since Dec 2006.
  • Of these, partial responses were observed in 4 pts (lung, melanoma x 2, gastric) and minor responses were observed in 2 pts (thyroid, ovarian).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963520.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Smylie M, Francis S, Neyns B, Maio M, Minor D, Verschraegen C, Chin K, Ibrahim R, Hoos A, Schadendorf D: Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels. J Clin Oncol; 2009 May 20;27(15_suppl):9041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels.
  • Ipilimumab is clinically active in advanced melanoma, with a 1-year survival rate of ∼50% in Phase II studies (Wolchok et al. CRI-CVC annual meeting 2008.
  • Serum LDH level is an independent prognostic factor for malignant melanoma, and is strongly predictive of reduced survival in stage IV disease (Bedikian et al.
  • This analysis evaluated the association between baseline LDH levels and disease control (stable or reduced measurable tumor burden) in previously treated pts with M1c-stage melanoma (metastasis to vital organs other than the lungs) who received ipilimumab in 2 recently completed Phase II studies (CA184008 and 022).
  • In study 022, pts were randomized to receive ipilimumab induction dosing at 0.3, 3.0, or 10 mg/kg Q3W × 4; study 008 was a single- arm trial of ipilimumab at 10 mg/kg.
  • Ipilimumab therefore appears to have clinical activity in the form of disease control in pts with a very poor prognosis, i.e., M1c-stage melanoma and elevated LDH levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962108.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. O'Day S, Weber J, Lebbe C, Maio M, Pehamberger H, Harmankaya K, Siegel J, Hoos A, Humphrey R, Wolchok J: Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):9033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials.
  • Updated survival data (≤32.5 months follow-up) from 3 Phase II trials of ipilimumab in pts with mostly pretreated advanced melanoma are reported.
  • METHODS: Study CA184008 was an open-label, single-arm study of ipilimumab 10 mg/kg.
  • CONCLUSIONS: Ipilimumab may result in a long-term survival benefit in pts with advanced melanoma, where 18-month survival rates across 3 Phase II studies range from 34.5% to 39.4% for previously treated pts.
  • These results indicate that more than 1/3 of ipilimumab-treated pts with advanced melanoma experience a long-term survival benefit, including some pts characterized as PD by mWHO.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Zatloukal P, Heo DS, Park K, Kang J, Butts C, Bradford D, Graziano S, Huang B, Healey D: Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8071

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tremelimumab, a fully human anti-CTLA4 mAb, is associated with durable responses in some pts with metastatic melanoma.
  • Although PFS analysis did not demonstrate superiority of tremelimumab over BSC, the 4.8% objective response rate seen only in the investigational arm may support future combination studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962647.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Schellens JH, Leijen S, Shapiro GI, Pavlick AC, Tibes R, O'Day SJ, Demuth T, Viscusi J, Xu Y, Oza AM: A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 28 evaluable pts, >50% regression of axillary lymphadenopathy was seen in 1 pt with melanoma on the P arm, and stable disease in 14 other pts (median duration).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Mohr P, Hauschild A, Rass K, Trefzer U, Enk A, Haalck T, Koller J, Gutzmer R, Küchler T, Weichenthal M, DeCOG Melanoma Study Group: Quality-of-life (QoL) impairment in melanoma patients receiving high-dose interferon alpha 2b (IFNa2b). J Clin Oncol; 2009 May 20;27(15_suppl):e20011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality-of-life (QoL) impairment in melanoma patients receiving high-dose interferon alpha 2b (IFNa2b).
  • : e20011 Background: High-dose interferon (HDI) for patients with malignant melanoma (MM) has consistently demonstrated benefits as an adjuvant treatment.
  • In the pulsed arm, 3 courses of IFNα2b, 20 Mio IU/m<sup>2</sup> iv 5 days a wk for 4 wks, repeated every 4 months was administered, whereas the subcutaneous (sc) treatment was 10 Mio IU/m<sup>2</sup> 3 times a wk for 11 months, after 4 wks of iv therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962567.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Loquai C, Pavlick A, Lawson D, Gutzmer R, Richards J, Gore ME, de Boer CJ, Uhlar C, Lang Z, O'Day S, on the behalf of the CNTO 95 Investigators: Randomized phase II study of the safety and efficacy of a human anti-αv integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results. J Clin Oncol; 2009 May 20;27(15_suppl):9029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of the safety and efficacy of a human anti-αv integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results.
  • METHODS: Patients with Stage IV metastatic melanoma were randomized 1:1:1:1 to receive 5 or 10mg/kg CNTO 95 alone, or DTIC (1000mg/m<sup>2</sup>) + either 10mg/kg CNTO 95 or placebo administered intravenously once every 3 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity.
  • The median survival was 11.0 months for the patients in the CNTO 95+DTIC arm, 9.8 months and 14.9 months for the 5mg/kg and 10mg/kg arms, and 8.0 months for those in the DTIC control arm.
  • In patients with Stage IV metastatic melanoma, a trend toward improvement in PFS, OS and disease control was demonstrated with CNTO 95+DTIC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962098.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Lutzky J, Wolchok J, Hamid O, Lebbe C, Pehamberger H, Linette G, de Pril V, Ibrahim R, Hoos A, O'Day S: Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):9034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials.
  • In this report, a potential association between disease control (DC) or overall survival (OS) and irAEs in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in 3 Phase II clinical trials was explored.
  • In study 022, pts were randomized to 0.3, 3, and 10 mg/kg groups, whereas study 008 was a single-arm trial of ipilimumab 10 mg/kg.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962091.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Townsend AR, Millward M, Price T, Mainwaring P, Spencer A, Longenecker A, Palladino MA, Lloyd GK, Spear MA, Padrik P: Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J Clin Oncol; 2009 May 20;27(15_suppl):3582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm).
  • Stable disease was induced in 31% of patients, including one each with mantle cell, Hodgkin's lymphoma, follicular lymphoma, sarcoma, prostate carcinoma, and two with melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Gerami P, Mafee M, Lurtsbarapa T, Guitart J, Haghighat Z, Newman M: Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes. Arch Dermatol; 2010 Mar;146(3):273-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes.
  • OBJECTIVE: To evaluate the diagnostic sensitivity of fluorescence in situ hybridization (FISH) using probes targeting 6p25, 6q23, 11q13, and Cep6 in melanoma subtypes.
  • DESIGN: Blinded comparison of chromosomal copy number changes detected using FISH targeting 6p25, 6q23, 11q13, and Cep6 in benign nevi and melanoma subtypes.
  • PARTICIPANTS: One hundred ten individuals with benign nevi and 123 with melanoma (70 superficial spreading, 28 lentigo maligna, 22 nodular, and 3 acral lentiginous melanomas).
  • MAIN OUTCOME MEASURES: Sensitivity of previously developed criteria using FISH using probes targeting 6p25, 6q23, 11q13, and Cep6 in the melanoma subtypes.
  • CONCLUSIONS: Heterogeneous changes in melanoma occur at the molecular level, and the changes are different among melanoma subtypes.
  • Clonal abnormalities in chromosome 6 with increased copies of the short arm relative to the long arm are common in all melanoma subtypes, suggesting that isochromosome 6 is common in all variants of cutaneous melanoma subtypes.
  • [MeSH-major] Cyclin D1 / genetics. DNA, Neoplasm / analysis. DNA-Binding Proteins / genetics. In Situ Hybridization, Fluorescence / methods. Melanoma / diagnosis. Proto-Oncogene Proteins c-myb / genetics. Skin Neoplasms / diagnosis. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231497.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-myb; 0 / RREB1 protein, human; 0 / Transcription Factors; 136601-57-5 / Cyclin D1
  •  go-up   go-down


28. Kilic E, van Gils W, Lodder E, Beverloo HB, van Til ME, Mooy CM, Paridaens D, de Klein A, Luyten GP: Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci; 2006 Sep;47(9):3703-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytogenetic analyses in uveal melanoma.
  • PURPOSE: Uveal melanoma is one of the most frequently occurring primary intraocular malignancies in the Western world.
  • The most frequent chromosomal abnormalities involved chromosome 8 (53%); loss of chromosome 3, p-arm (41%) and q-arm (42%); partial loss of chromosome 1, p-arm (24%); and abnormalities in chromosome 6 that resulted in gain of 6p (18%) and/or loss of 6q (28%).
  • Less-frequent aberrations were abnormalities in chromosome 16, in particular loss of chromosome 16 q-arm (16%).
  • CONCLUSIONS: Monosomy 3 and largest tumor diameter are the most significant in determining survival of patients with uveal melanoma.
  • Abnormalities in the q-arm of chromosome 16 are relatively common in uveal melanoma, but are not associated with survival or other cytogenetic or histopathologic parameters.
  • [MeSH-major] Chromosome Aberrations. Melanoma / genetics. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936076.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol; 2010 Aug;21(8):1712-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
  • BACKGROUND: This phase II study evaluated the safety and activity of ipilimumab, a fully human mAb that blocks cytotoxic T-lymphocyte antigen-4, in patients with advanced melanoma.
  • PATIENTS AND METHODS: Patients with previously treated, unresectable stage III/stage IV melanoma received 10 mg/kg ipilimumab every 3 weeks for four cycles (induction) followed by maintenance therapy every 3 months.
  • CONCLUSION: Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20147741.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ipilimumab
  •  go-up   go-down


30. Blokx WA, Lesterhuis WJ, Andriessen MP, Verdijk MA, Punt CJ, Ligtenberg MJ: CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma. Am J Surg Pathol; 2007 Apr;31(4):637-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma.
  • The histologic differential diagnosis between a second primary cutaneous melanoma and cutaneous melanoma metastasis in a patient with a previous history of melanoma can be very difficult.
  • This case report describes the first application of CDKN2A mutation analysis for discriminating a cutaneous melanoma metastasis from a new primary melanoma.
  • In 2005, we received a skin excision of the right arm of a 38-year-old female patient for second opinion.
  • Histologically, we considered the lesion to be a melanoma.
  • The patient had a history of superficial spreading melanoma in the right subclavicular region, with a Breslow thickness of 1.1 mm, in 1998.
  • The morphology showed resemblance to the present melanoma on the right arm, but the differential diagnosis between metastasis or second primary melanoma could not be made with certainty based on histology alone.
  • Molecular analysis revealed that both the melanoma of 1998 and of 2005 contained an identical CDKN2A mutation (a deletion in exon 1alpha, c.95_112del (p.Leu32_Leu37del)), which was absent in normal control tissue of the patient, thereby excluding a germline mutation.
  • Based on these molecular findings the present melanoma on the right arm was diagnosed as a metastasis.
  • This case illustrates that molecular analysis can contribute to the sometimes-difficult differentiation between a second primary melanoma and a melanoma metastasis.
  • [MeSH-major] Genes, p16. Melanoma / genetics. Melanoma / secondary. Neoplasms, Second Primary / genetics. Neoplasms, Second Primary / pathology. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2007 Jul;31(7):1137. Lesterhuis, Joost J [corrected to Lesterhuis, W Joost]; Punt, Kees J A [corrected to Punt, Cornelis J A]
  • (PMID = 17414113.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Price KL, Herlyn M, Dent CL, Gewert DR, Linge C: The prevalence of interferon-alpha transcription defects in malignant melanoma. Melanoma Res; 2005 Apr;15(2):91-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of interferon-alpha transcription defects in malignant melanoma.
  • The type I interferons, interferon-alpha (IFN-alpha) and interferon-beta (IFN-beta), are situated on the short arm of chromosome 9, specifically 9p21-22.
  • The identification of 9p rearrangements in both melanoma precursor lesions (dysplastic naevi) and primary lesions has implicated the 9p locus in the early stages of melanoma development.
  • Recent evidence has demonstrated that metastatic melanoma cell lines have a specific loss of IFN-alpha gene expression, a defect that appears to occur at the level of transcription.
  • In this study, we examined the expression of IFN-alpha in cell lines isolated from the various stages of melanoma progression, with a view to determine the prevalence of the IFN-alpha transcription defects exhibited by malignant melanoma, and to assess whether the loss of IFN-alpha expression was particular to a certain stage of melanoma progression.
  • We showed that all the melanoma cell lines tested (n=20) demonstrated an inability to express IFN-alpha, a defect that was reflected in the apparent inactivity of the IFN-alpha promoter.
  • These defects were found to occur in cells isolated from early melanomas, lending support to the hypothesis that IFN-alpha has a role in the aetiology of malignant melanoma.
  • [MeSH-major] Antineoplastic Agents. Gene Expression Regulation, Neoplastic. Interferon-alpha / genetics. Melanoma / genetics. Skin Neoplasms / genetics. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846141.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / Interferon-alpha; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


32. Gall N, Bröcker EB, Becker JC: Particularities in managing melanoma patients with tattoos: case report and review of the literature. J Dtsch Dermatol Ges; 2007 Dec;5(12):1120-1
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Particularities in managing melanoma patients with tattoos: case report and review of the literature.
  • Patients with tattoos may provide a challenge in the early recognition and follow-up of melanoma.
  • [MeSH-major] Dermoscopy. Melanoma / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis. Tattooing / adverse effects
  • [MeSH-minor] Adult. Arm. Coloring Agents / analysis. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Male. Neoplasm Invasiveness. Neoplasm Staging. Reoperation. Skin / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919304.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coloring Agents
  • [Number-of-references] 8
  •  go-up   go-down


33. Mensing C, Livingstone E, Schwarz T, Hauschild A: Eczematous malignant melanoma: a wolf in sheep's clothing. Onkologie; 2009 Apr;32(4):206-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eczematous malignant melanoma: a wolf in sheep's clothing.
  • BACKGROUND: The clinical diagnosis of amelanotic melanoma is still a challenge.
  • CASE REPORT: A 72-year-old patient was first referred to us for the excision of a melanoma of the chin.
  • In the first examination, we discovered another melanoma of the trunk.
  • Apart from these melanomas, physical examination revealed an 8 cm x 5 cm large erythematous plaque on the left upper arm.
  • Surprisingly, the pathology report showed typical features of a malignant melanoma.
  • CONCLUSIONS: Amelanotic melanoma may appear as an erythematous macula or plaque; clinical symptoms are erythema, edema, pruritus or a slow increase in size and hypopigmentation or discoloration.
  • [MeSH-major] Eczema / diagnosis. Eczema / etiology. Melanoma / complications. Melanoma / diagnosis. Skin Neoplasms / complications. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Eczema.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19372718.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Duarte AF, Correia O, Barros AM, Azevedo R, Haneke E: Nail matrix melanoma in situ: conservative surgical management. Dermatology; 2010;220(2):173-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nail matrix melanoma in situ: conservative surgical management.
  • BACKGROUND: Nail unit melanoma (NUM) is a rare variant of acral lentiginous melanoma.
  • The differential diagnosis is wide but an acquired brown streak in the nail of a fair-skinned person must be considered a potential melanoma.
  • An excisional biopsy was performed, and pathological examination revealed melanoma in situ.
  • For safety reasons, the nail unit was totally removed down to the phalangeal bone 3 weeks later, and a full-thickness skin graft taken from the arm was used for reconstruction.
  • Wide excision with phalanx amputation is not satisfactory for patients with in situ and early invasive melanoma.
  • [MeSH-major] Melanoma / surgery. Nail Diseases / surgery. Skin Neoplasms / surgery. Skin Transplantation / methods

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatology. 2011;223(2):122-3 [21846959.001]
  • (PMID = 20016126.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


35. Kim JY, Ross MI, Butler CE: Reconstruction following radical resection of recurrent metastatic axillary melanoma. Plast Reconstr Surg; 2006 Apr 15;117(5):1576-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstruction following radical resection of recurrent metastatic axillary melanoma.
  • BACKGROUND: Recurrent axillary metastasis following axillary lymphadenectomy for melanoma is associated with a poor prognosis.
  • METHODS: A retrospective review of all patients who underwent axillary reexcision and reconstruction for metastatic melanoma between 1990 and 2000 was conducted at The University of Texas M. D.
  • [MeSH-major] Melanoma / surgery. Neoplasm Recurrence, Local / surgery. Reconstructive Surgical Procedures. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Amputation. Arm / surgery. Axilla. Chemotherapy, Adjuvant. Humans. Lymph Node Excision. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Surgical Mesh. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16641728.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Mensink HW, Kiliç E, Vaarwater J, Douben H, Paridaens D, de Klein A: Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome. Cancer Genet Cytogenet; 2008 Mar;181(2):108-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome.
  • Uveal melanoma (UM) is the most common primary intraocular tumor in the Western world.
  • In 44 tumors aberrations were present and classic prognostic markers as loss of 1p (12 tumors, 26.1%), monosomy 3 (26 tumors, 56.5%), loss of 6q (10 tumors, 21.7%), and gain of chromosome arm 8q (27 tumors, 58.7%) were observed.
  • [MeSH-major] Chromosome Aberrations. Melanoma / genetics. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18295662.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Mensink HW, Vaarwater J, Kiliç E, Naus NC, Mooy N, Luyten G, Brüggenwirth HT, Paridaens D, de Klein A: Chromosome 3 intratumor heterogeneity in uveal melanoma. Invest Ophthalmol Vis Sci; 2009 Feb;50(2):500-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 3 intratumor heterogeneity in uveal melanoma.
  • PURPOSE: To investigate the presence of focal or diffuse heterogeneity of monosomy 3 in uveal melanoma, by using fluorescence in situ hybridization (FISH).
  • Tumors with monosomy 3 were suspected to be heterogeneous if there were low percentages of monosomy 3, triploid clones, inconsistencies between FISH on centromere 3 and the long arm of chromosome 3, or discrepancies between fine-needle-aspiration biopsies (FNABs) and the main tumor.
  • In general, tumor biopsies in uveal melanoma provide an accurate prediction of the patient's prognosis.
  • [MeSH-major] Choroid Neoplasms / genetics. Chromosomes, Human, Pair 3 / genetics. Genetic Heterogeneity. Melanoma / genetics. Monosomy / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824727.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Meyer BC, Frericks BB, Voges M, Borchert M, Martus P, Justiz J, Wolf KJ, Wacker FK: Visualization of hypervascular liver lesions During TACE: comparison of angiographic C-arm CT and MDCT. AJR Am J Roentgenol; 2008 Apr;190(4):W263-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visualization of hypervascular liver lesions During TACE: comparison of angiographic C-arm CT and MDCT.
  • OBJECTIVE: The purpose of our study was to evaluate the diagnostic accuracy and scan coverage of flat-detector C-arm CT compared with that of biphasic MDCT for depicting malignant hepatic lesions in patients with hypervascular liver tumors before they undergo transarterial chemoembolization (TACE).
  • MATERIALS AND METHODS: Fifteen patients with either hepatocellular carcinoma (HCC, n = 8) or hypervascular liver metastases from uveal melanoma (n = 7) underwent arterial and portal venous C-arm CT of the liver using intraarterial contrast media administration directly before TACE.
  • Complete scan coverage of the liver was obtained in five of the 15 patients with C-arm CT.
  • In patients with incomplete scan coverage on C-arm CT, the craniocaudal liver diameter was significantly larger than in those patients with complete scan coverage (mean [95% CI], 22.7 [19.5-25.9] cm vs 20.2 [15.4-25.0] cm, p = 0.0193).
  • CONCLUSION: Biphasic arterial and portal venous C-arm CT showed a high sensitivity for the detection of malignant liver lesions.
  • Therefore, the current scan range limitations need to be overcome to make C-arm CT a valuable adjunct to MDCT for preprocedure evaluation and postprocedure follow-up imaging.
  • [MeSH-minor] Adult. Aged. Contrast Media. Diagnosis, Differential. False Positive Reactions. Female. Humans. Iohexol / analogs & derivatives. Male. Melanoma / radiography. Melanoma / secondary. Melanoma / therapy. Middle Aged. Radiographic Image Interpretation, Computer-Assisted. Sensitivity and Specificity. Statistics, Nonparametric. Treatment Outcome. Uveal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356419.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


39. Kroon HM, Lin DY, Kam PC, Thompson JF: Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Ann Surg; 2009 Jun;249(6):1008-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
  • INTRODUCTION: The treatment of elderly patients with advanced metastatic melanoma confined to a limb remains controversial.
  • METHODS: From our prospective database 185 patients with advanced metastatic melanoma of the limb treated with a single ILI between 1992 and 2007 were identified.
  • CONCLUSIONS: Elderly patients with advanced metastatic melanoma of the limb experience the same or lower toxicity after ILI compared with younger patients while response rates, limb recurrence free interval, survival, and morbidity are similar.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Melanoma / drug therapy. Melanoma / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Arm. Cohort Studies. Female. Humans. Hyperthermia, Induced. Infusions, Intra-Arterial. Leg. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474677.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Khammari A, Nguyen JM, Pandolfino MC, Quereux G, Brocard A, Bercegeay S, Cassidanius A, Lemarre P, Volteau C, Labarrière N, Jotereau F, Dréno B: Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother; 2007 Nov;56(11):1853-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
  • The first analysis of our clinical trial on interest of using tumor-infiltrating lymphocytes (TIL) as adjuvant therapy for stage III (regional lymph nodes) melanoma was published in 2002 [5].
  • In the group with only one invaded lymph node, the estimated relapse rate was significantly lower (P (adjusted) = 0.0219) and the overall survival was increased (P (adjusted) = 0.0125) in the TIL+IL-2 arm compared with the IL-2 only arm.
  • This study, with a very long follow up (median of almost 10 years), postulates for the first time relationship between TIL efficiency in stage III melanoma (AJCC) and number of invaded lymph nodes, indicating that tumor burden might be a crucial factor in the production of an effective in vitro expansion of T cells specific for autologous tumor antigen, a finding which could be of value in future vaccine development for the treatment of melanoma.
  • [MeSH-major] Adjuvants, Immunologic. Adoptive Transfer. Lymphocytes, Tumor-Infiltrating / immunology. Melanoma / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549472.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic
  •  go-up   go-down


41. Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS: Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol; 2008 Apr;31(2):173-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
  • OBJECTIVE: To evaluate the safety and activity of large multivalent immunogen (LMI), prepared by immobilizing autologous tumor cell plasma membrane on 5-microm diameter silica beads, in patients with melanoma and renal cell carcinoma (RCC).
  • METHODS: Thirty patients with stage IV metastatic melanoma and 31 patients with stage IV RCC were randomly assigned to 1 of 3 trial arms and received monthly treatment with (1) LMI alone, (2) cyclophosphamide followed 8 days later with LMI, or (3) the same treatment as in arm 2 with IL-2 given for 5 days beginning 1 week after LMI administration.
  • For patients with melanoma, median overall survival time for all 30 patients was 20.4 months [95% confidence interval (CI): 8.0-not assessable], and median progression-free survival was 2.8 months (95% CI: 1.9-6.3).
  • [MeSH-major] Antigens, Neoplasm / therapeutic use. Cancer Vaccines / therapeutic use. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy. Melanoma / therapy. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391603.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Interleukin-2; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


42. Koynova DK, Jordanova ES, Milev AD, Dijkman R, Kirov KS, Toncheva DI, Gruis NA: Gene-specific fluorescence in-situ hybridization analysis on tissue microarray to refine the region of chromosome 20q amplification in melanoma. Melanoma Res; 2007 Feb;17(1):37-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-specific fluorescence in-situ hybridization analysis on tissue microarray to refine the region of chromosome 20q amplification in melanoma.
  • Several comparative genomic hybridization studies provide evidence for overrepresentation of the long arm of chromosome 20 in malignant melanoma.
  • These studies also suggest that chromosome 20q contains genes that may contribute to melanoma pathogenesis.
  • To refine the region of 20q amplification and to identify potential candidate genes involved in melanoma or even in melanoma progression from these regions, we combined fluorescence in-situ hybridization with MYBL2, ZNF217, CYP24 and STK6 specific probes (chromosomal region 20q13.1-q13.2) with high-throughput tissue microarray consisting of 280 primary melanomas and melanoma metastases.
  • Despite the technological advantage of fluorescence in-situ hybridization on tissue microarray, which allows refining regions of amplification, we were not able to recognize any of the MYBL2, ZNF217, CYP24 and STK6 genes as a particular relevant gene for melanoma tumorigenesis.
  • [MeSH-major] Chromosome Mapping. Chromosomes, Human, Pair 20. Melanoma / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235240.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


43. Stang A, Pukkala E, Sankila R, Söderman B, Hakulinen T: Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases. Int J Cancer; 2006 Jul 15;119(2):380-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases.
  • Site-specific analyses of the skin melanoma incidence show marked differences between men and women by site and over time.
  • The aim of our study was to analyze long-term population-based incidence time trends of skin melanoma in Finland over a period of more than 50 years, with special emphasis on sex- and subsite-specific changes over time.
  • From 1953 through 2003, the incidence of skin melanoma increased from 1.5 to 12.8 per 100,000 among men and from 1.8 to 10.4 per 100,000 among women.
  • Within the skin area of the head, melanoma of the ear showed the highest relative increase among both men and women.
  • Only skin melanoma of the head showed an exponential age-specific incidence pattern and the aetiology of these skin melanomas may differ from skin melanoma on other subsites.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Arm. Back. Female. Finland / epidemiology. Head. Hip. Humans. Incidence. Leg. Male. Middle Aged. Sex Distribution. Sex Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16477634.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Bulliard JL, De Weck D, Fisch T, Bordoni A, Levi F: Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series. Ann Oncol; 2007 Apr;18(4):789-94
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series.
  • BACKGROUND: The relation between detailed cutaneous distribution of melanoma and indicators of sun exposure patterns has scantily been explored in moderately sun-sensitive populations.
  • PATIENTS AND METHODS: The precise site of 1658 primary malignant melanoma, registered from 1995 to 2002, in Switzerland were retrieved and clinically validated.
  • Relative melanoma density (RMD) was computed by the ratio of observed to expected number of melanoma allowing for body site surface areas, and further adjusted for site-specific melanocyte density.
  • RESULTS: Sites of highest risks were the face, shoulder and upper arm for both sexes, the back for men, and leg for women.
  • Major features of this series were: (i) an unexpectedly high RMD for the face in women (5.6 versus 3.7 in men), (ii) the absence of a male predominance for melanoma on the ears and (iii) for the upper limbs, a steady gradient of increasing melanoma density with increasing proximity to the trunk, regardless of sex.
  • CONCLUSION: RMD increased with (cumulative) site sun exposure, but a few notable exceptions support the impact of intermittent exposure in melanoma risk.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237475.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. van Gils W, Lodder EM, Mensink HW, Kiliç E, Naus NC, Brüggenwirth HT, van Ijcken W, Paridaens D, Luyten GP, de Klein A: Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Invest Ophthalmol Vis Sci; 2008 Oct;49(10):4254-62
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.
  • PURPOSE: Although studies on uveal melanoma (UM) revealed prognostic significance of chromosomal aberrations, they resulted in classification errors in survival prediction.
  • A locally adaptive statistical procedure identified two regions on the short arm of chromosome 3 with decreased gene-expression in tumors with shorter disease-free survival.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / physiology. Melanoma / genetics. Oligonucleotide Array Sequence Analysis. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552379.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM: The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer; 2006 Jan 1;106(1):156-62
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
  • BACKGROUND: Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically.
  • In patients with extremity STS or bulky melanoma in-transit metastases, the local tumor burden may be so problematic that, even in patients with systemically metastasized disease, an amputation may be inevitable.
  • In this study, the authors investigated the palliative value of the ILP procedure to avoid amputation in patients who had Stage IV STS and melanoma.
  • METHODS: From 1991 to 2003, of 339 tumor necrosis factor alpha (TNF)-based ILPs, 51 procedures were performed for either Stage IV STS (n = 37 patients) or Stage IV melanoma (n = 14 patients).
  • In the patients with Stage IV melanoma, the complete response rate was 43%.
  • All patients with melanoma preserved their limb during a median survival of 7 months.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / therapeutic use. Palliative Care. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation. Arm. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


47. Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR: Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol; 2007 Jun 20;25(18):2540-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
  • PURPOSE: To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma.
  • PATIENTS AND METHODS: Patients with unresectable stage III or IV cutaneous melanoma who had no prior systemic chemotherapy were randomly assigned to receive either 40 to 80 mg LM and 125 mg/m2 TMZ or 200 mg/m2 TMZ on days 1 through 5 of each 28-day treatment cycle.
  • RESULTS: One hundred four patients were enrolled, with 52 in each trial arm.
  • A higher incidence of hematological adverse events was observed in the LM/TMZ combination arm.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / analogs & derivatives. Enzyme Inhibitors / administration & dosage. Melanoma / drug therapy. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577032.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Purines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; S79265T71M / lomeguatrib
  •  go-up   go-down


48. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE: Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol; 2007 May 20;25(15):2078-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
  • PURPOSE: To compare the overall survival (OS) of patients with resected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved using high-dose IFN-alpha-2b.
  • PATIENTS AND METHODS: An Ad Hoc Melanoma Working Group of 25 investigators treated 604 patients from April 1997 to January 2003.
  • Patients were stratified by sex and number of nodes and were randomly assigned to receive either 2 years of treatment with active specific immunotherapy with allogeneic melanoma lysates and low-dose IFN-alpha-2b (arm 1) or high-dose IFN-alpha-2b alone for 1 year (arm 2).
  • IFN-alpha-2b in arm 2 was administered according to the Eastern Cooperative Oncology Group 1684 study regimen.
  • Median OS time exceeds 84 months in arm 1 and is 83 months in arm 2 (P = .56).
  • Five-year OS rate is 61% in arm 1 and 57% in arm 2.
  • Estimated 5-year relapse-free survival (RFS) rate is 50% in arm 1 and 48% in arm 2, with median RFS times of 58 and 50 months, respectively.
  • The incidence of serious adverse events as a result of treatment was the same in both arms, but more severe neuropsychiatric toxicity was seen in arm 2.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy, Active. Interferon-alpha / therapeutic use. Melanoma / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Expert Rev Vaccines. 2007 Dec;6(6):907-11 [18377354.001]
  • [CommentIn] J Clin Oncol. 2007 Oct 10;25(29):4693; author reply 4693-5 [17925569.001]
  • (PMID = 17513813.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytoskeletal Proteins; 0 / Drug Combinations; 0 / Interferon-alpha; 0 / Lipid A; 0 / Melacine; 0 / Recombinant Proteins; 0 / detox adjuvant; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


49. Velasco-Velázquez MA, Salinas-Jazmín N, Mendoza-Patiño N, Mandoki JJ: Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells. Cancer Cell Int; 2008;8:8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells.
  • 4-HC affects the cytoskeletal stability and decreases cell adhesion and motility of the melanoma cell line B16-F10.
  • The present study determined the participation of paxillin in the reported effects of 4-HC and analyzed the role of paxillin in the formation of melanoma metastases.
  • We also studied the importance of paxillin in metastasis by transfecting melanoma cells with paxillin-siRNA.
  • Transfection produced a modest reduction on metastatic potential, indicating that: i) paxillin plays a role as inducer of melanoma metastasis; and ii) paxillin downregulation is not sufficient to explain the antimetastatic effect of 4-HC.
  • Treatment with 4-HC produced a downregulation of Adhesion Regulating Molecule-1 (ARM-1), which correlated with a decreased adhesion of melanoma cells to lung slides.
  • In contrast, the role of ARM-1 reduced expression in the effects of 4-HC is still to be clarified.
  • The antimetastatic effect of 4-HC suggests that this compound, or others with similar mode of action, might be useful for the development of adjuvant therapies for melanoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 1994 Jan;89(1):432-49 [8281678.001]
  • [Cites] Physiol Rev. 2004 Oct;84(4):1315-39 [15383653.001]
  • [Cites] Connect Tissue Res. 1996;34(3):161-74 [9023046.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7437-44 [9054445.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):6906-14 [9372922.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22435-41 [9712867.001]
  • [Cites] Genes Dev. 1998 Nov 1;12(21):3331-6 [9808620.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):67-77 [9926921.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2843-6 [10383144.001]
  • [Cites] Mol Biol Cell. 1999 Aug;10(8):2507-18 [10436008.001]
  • [Cites] Rev Invest Clin. 1999 May-Jun;51(3):183-93 [10466009.001]
  • [Cites] J Cell Biol. 2000 Mar 6;148(5):957-70 [10704446.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):27155-64 [10823820.001]
  • [Cites] Clin Exp Metastasis. 1999;17(8):641-8 [10919708.001]
  • [Cites] Mol Biol Cell. 2000 Sep;11(9):3247-63 [10982414.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68 [15688067.001]
  • [Cites] Protein Sci. 2005 Mar;14(3):644-52 [15689512.001]
  • [Cites] World J Gastroenterol. 2005 Mar 14;11(10):1445-51 [15770719.001]
  • [Cites] FEBS J. 2005 Apr;272(8):1833-44 [15819879.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4754-64 [15870699.001]
  • [Cites] Clin Exp Immunol. 2005 Jun;140(3):443-9 [15932505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11041-6 [16040804.001]
  • [Cites] J Proteome Res. 2005 Sep-Oct;4(5):1832-41 [16212439.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9851-60 [16267008.001]
  • [Cites] J Cell Sci. 2005 Dec 15;118(Pt 24):5835-47 [16317044.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):9-15 [16360410.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):629-43 [16375667.001]
  • [Cites] Oncogene. 2006 Jun 22;25(26):3689-98 [16462764.001]
  • [Cites] J Cell Biochem. 2006 Aug 15;98(6):1507-16 [16552730.001]
  • [Cites] J Mol Biol. 2006 Jul 28;360(5):1043-52 [16815440.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Oct 6;348(4):1463-71 [16920067.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):163-80 [17084981.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):38040-7 [10986280.001]
  • [Cites] Nat Cell Biol. 2000 Dec;2(12):E231-6 [11146675.001]
  • [Cites] Nat Protoc. 2006;1(5):2315-9 [17406473.001]
  • [Cites] Ecotoxicol Environ Saf. 1986 Feb;11(1):91-9 [3956434.001]
  • [Cites] Mol Cell Biol. 1995 May;15(5):2635-45 [7537852.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):104-8 [7615962.001]
  • [Cites] Lab Invest. 1993 Feb;68(2):192-203 [7680081.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3831-6 [8033103.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):917-23 [11396185.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):793-805 [11715046.001]
  • [Cites] Int J Cancer. 2002 Jan 20;97(3):330-5 [11774284.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(3):901-15 [11784865.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34391-400 [12110680.001]
  • [Cites] J Cell Biol. 2002 Nov 25;159(4):673-83 [12446743.001]
  • [Cites] Biochim Biophys Acta. 2003 Feb 17;1593(2-3):115-20 [12581855.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Scand J Immunol. 2003 May;57(5):439-45 [12753500.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):683-9 [12866027.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):359-74 [12884911.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):690-2 [12894172.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):179-86 [12957356.001]
  • [Cites] Science. 1992 Aug 14;257(5072):967-71 [1354393.001]
  • [Cites] J Cell Biol. 1992 Nov;119(4):893-903 [1385444.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1704-9 [14657486.001]
  • [Cites] BMC Cancer. 2004 May 7;4:18 [15132756.001]
  • [Cites] Fundam Clin Pharmacol. 1996;10(6):504-10 [8985719.001]
  • (PMID = 18492274.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2429896
  •  go-up   go-down


50. King R, Googe PB, Page RN, Mihm MC Jr: Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ. Mod Pathol; 2005 Aug;18(8):1043-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ.
  • A single case of lentiginous melanocytic hyperplasia overlying a dermatofibroma has been reported, however, nevi and melanoma have to the best of our knowledge, not been previously reported.
  • There were nine females and five males ranging in age from 30 to 64 years and anatomic sites included back (five), arm (six), flank (two), and leg (one).
  • The clinical diagnosis ranged from dermatofibroma to desmoplastic melanoma.
  • Histologically, the melanocytic lesions included junctional, compound, and dermal nevi, and malignant melanoma in situ.
  • In the case of the melanoma in situ, the dermatofibroma abutted the epidermis.
  • [MeSH-minor] Adult. Antigens, Neoplasm. Factor XIIIa / analysis. Female. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma / metabolism. Melanoma / pathology. Middle Aged. Neoplasm Proteins / analysis. Nevus / metabolism. Nevus / pathology. Proto-Oncogene Proteins c-kit / analysis. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803191.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / S100 Proteins; EC 2.3.2.13 / Factor XIIIa; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


51. Kirsch A: Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M). J Altern Complement Med; 2007 May;13(4):443-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M).
  • BACKGROUND: Recent study results demonstrate possible clinical benefit from adjuvant treatment with a standardized mistletoe (Viscum album) extract in patients with malignant melanoma.
  • PATIENT AND METHOD: We present a male patient, currently 68 years of age, with one malignant melanoma at the upper part of the right arm since 1992, and another nodular melanoma at the left shoulder, first diagnosed in 1999.
  • After discovery of the second melanoma and surgical resection, the patient was exclusively treated with standardized mistletoe extract (Iscador, (R)M; Weleda AG, CH-Arlesheim, Switzerland).
  • COURSE OF THERAPY AND RESULTS: In June 1992, histologic analysis confirmed the presence of stage IA superficially spreading malignant melanoma with low infiltration of the papillary dermis in a skin excision sample from the upper part of the right arm.
  • In November 1999, another melanoma was surgically removed at the patient's right shoulder.
  • In this case, the histologic examination revealed nodular melanoma, stage IIA (pT3, pN0, M0).
  • CONCLUSIONS: The use of low-dose Iscador as the sole postoperative modality for the adjuvant treatment of metastatic melanoma was extremely effective and very well tolerated in this patient.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Melanoma / drug therapy. Melanoma / secondary. Plant Extracts / administration & dosage. Plant Proteins / administration & dosage. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532738.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic; 0 / Antineoplastic Agents; 0 / Plant Extracts; 0 / Plant Proteins; 0 / viscum album peptide
  •  go-up   go-down


52. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A: Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol; 2009 Mar 1;27(7):1075-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of tremelimumab in patients with metastatic melanoma.
  • PATIENTS AND METHODS: Twenty-eight patients with metastatic melanoma received monthly intravenous infusions of tremelimumab at 3, 6, or 10 mg/kg for up to 1 year to determine recommended monthly phase II dose.
  • Frequency of grade 3/4 AEs was 13% in the 15 mg/kg every 3 months arm and 27% in the 10 mg/kg once every month.
  • Serious AEs were also less frequent in the 15 mg/kg once every 3 months cohort (9% v 23% in 10 mg/kg arm).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA128953; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / CA 87558
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; QEN1X95CIX / tremelimumab
  •  go-up   go-down


53. van Gils W, Mensink HW, Kilic E, Vaarwater J, Verbiest MM, Paridaens D, Luyten GP, de Klein A, Brüggenwirth HT: Expression of APITD1 is not related to copy number changes of chromosomal region 1p36 or the prognosis of uveal melanoma. Invest Ophthalmol Vis Sci; 2007 Nov;48(11):4919-23
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of APITD1 is not related to copy number changes of chromosomal region 1p36 or the prognosis of uveal melanoma.
  • PURPOSE: Concurrent loss of chromosome arm 1p, region 36, and chromosome 3 leads to decreased disease-free survival in patients with uveal melanoma.
  • A candidate tumor-suppressor gene APITD1 is located on the critical region on chromosome arm 1p, and it was therefore hypothesized that lower expression levels of this gene could lead to decreased survival in patients, with concurrent loss of a region on chromosome arm 1p and chromosome 3.
  • Using neuroblastoma cells, which, like uveal melanoma, originate from neural crest cells, a former study showed that APITD1 has cell growth and/or cell death properties.
  • In this study, APITD1 expression was analyzed to determine whether it corresponds with the DNA copy number and is related to survival in uveal melanoma.
  • CONCLUSIONS: These results indicate that APITD1 is not the tumor suppressor gene on 1p36 responsible for the negative prognostic effect in uveal melanoma with concurrent loss of chromosome arm 1p, region 36, and chromosome 3.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Chromosomes, Human, Pair 1 / genetics. Gene Dosage / genetics. Gene Expression Regulation, Neoplastic. Melanoma / genetics. Tumor Suppressor Proteins / genetics. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962439.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APITD1 protein, human; 0 / Apoptosis Regulatory Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


54. Geller AC, Emmons KM, Brooks DR, Powers C, Zhang Z, Koh HK, Heeren T, Sober AJ, Li F, Gilchrest BA: A randomized trial to improve early detection and prevention practices among siblings of melanoma patients. Cancer; 2006 Aug 15;107(4):806-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial to improve early detection and prevention practices among siblings of melanoma patients.
  • BACKGROUND: Identifying high-risk individuals for melanoma education and risk reduction may be a viable strategy to curb the incidence of melanoma, which has risen precipitously in the past 50 years.
  • The first-degree relatives of melanoma patients represent a risk group who may experience a 'teachable moment' for enhanced education and risk reduction.
  • METHODS: We report a randomized trial testing an intervention that provided personalized telephone counseling and individually tailored materials to siblings of recently-diagnosed melanoma patients.
  • Families in the usual care arm received the suggestion from the physician that patients diagnosed with melanoma notify the family members about their diagnosis and encourage the family members to be screened.
  • CONCLUSIONS: This study is the one of the first, to our knowledge, to address skin cancer risk-reduction strategies in a sample of individuals who have a recent family diagnosis of melanoma.
  • Diagnosis of melanoma in a family member provides an important opportunity to intervene with others in that family.
  • The components of the intervention may provide a useful foundation for future efforts to target the more than half million siblings at risk for melanoma, a lethal but preventable disease.
  • [MeSH-major] Health Knowledge, Attitudes, Practice. Melanoma / diagnosis. Melanoma / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832795.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA76333
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


55. Russo A, Coupland SE, O'Keefe M, Damato BE: Choroidal melanoma in a 7-year-old child treated by trans-scleral local resection. Graefes Arch Clin Exp Ophthalmol; 2010 May;248(5):747-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal melanoma in a 7-year-old child treated by trans-scleral local resection.
  • PURPOSE: To report a choroidal melanoma in a 7-year-old child treated by trans-scleral local resection and adjuvant brachytherapy with a family history of neurofibromatosis type I (NF1) and cutaneous melanoma.
  • PATIENT AND METHODS: A 7-year-old child was referred for treatment of a choroidal tumor in her left eye with a differential diagnosis of melanoma, neurilemmoma, leiomyoma, and neurofibroma.
  • RESULTS: Histopathology and immunohistochemistry of the specimen diagnosed an amelanotic melanoma of spindle cell type, with a moderately high number of mitoses (7/40 HPF).
  • Multiplex ligation-dependent probe amplification (MLPA) analysis showed two copies of chromosome 3, three copies of the short arm of chromosome 6, and two copies of chromosome 8, strongly suggesting a good prognosis.
  • [MeSH-major] Choroid Neoplasms / surgery. Melanoma / surgery. Ophthalmologic Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Ophthalmol (Copenh). 1970;48(6):1113-28 [5537253.001]
  • [Cites] Ann Surg. 1972 Jan;175(1):86-104 [4621893.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2007 Apr;245(4):522-33 [17111148.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):918-23 [10900104.001]
  • [Cites] Ophthalmology. 1991 Nov;98(11):1662-6 [1800926.001]
  • [Cites] Am J Ophthalmol. 1998 Jun;125(6):745-66 [9645714.001]
  • [Cites] Arch Ophthalmol. 1981 Dec;99(12):2133-6 [7305710.001]
  • [Cites] Arch Ophthalmol. 2009 Apr;127(4):423-9 [19365018.001]
  • (PMID = 20143236.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ruthenium Radioisotopes
  •  go-up   go-down


56. Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE: In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br J Dermatol; 2006 Dec;155(6):1287-92
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ photoimmunotherapy: a tumour-directed treatment for melanoma.
  • We report a new immunological treatment for advanced cutaneous melanoma which combines laser stimulation with topical application of a toll-like receptor agonist.
  • This treatment, in situ photoimmunotherapy (ISPI), provides an alternative to traditional therapies for melanoma patients with cutaneous metastases.
  • Two patients with late-stage melanoma were treated with ISPI.
  • Patient 1 had the primary tumour and local metastases on the left arm, as well as metastatic tumours in the lungs [American Joint Committee on Cancer (AJCC) stage IV].
  • Patient 2 had a head and neck melanoma with multiple local metastases (AJCC stage IIIC), which had failed repeated attempts at surgical resection and high-dose radiation therapy.
  • These two cases demonstrate that ISPI can clear local tumour and trigger beneficial systemic responses, with a side-effect profile that compares favourably with other treatments for advanced melanoma.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Melanoma / therapy. Photochemotherapy / methods. Skin Neoplasms / therapy. Toll-Like Receptors / agonists

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107404.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016478
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / Toll-Like Receptors; 99011-02-6 / imiquimod
  •  go-up   go-down


57. Danino AM, Kadlub N, Dalac S, Boichot C, Malka G: Reducing the number of sentinel nodes removed in melanoma patients: a prospective study. Indian J Cancer; 2006 Jul-Sep;43(3):132-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing the number of sentinel nodes removed in melanoma patients: a prospective study.
  • CONTEXT: Since 1992, sentinel lymph node (SLN) biopsy was generally applied to melanoma for tumor staging.
  • MATERIALS AND METHODS: We conducted a single-arm prospective study in patients with stage I melanoma.
  • We analyzed the characteristics of each melanoma, the success rate of this procedure, how many nodes were removed and how many had micro metastases.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / pathology. Sentinel Lymph Node Biopsy / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065772.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  •  go-up   go-down


58. Quirt I, Verma S, Petrella T, Bak K, Charette M: Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist; 2007 Sep;12(9):1114-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide for the treatment of metastatic melanoma: a systematic review.
  • BACKGROUND: This systematic review examines the role of temozolomide in patients with metastatic melanoma.
  • METHODS: The MEDLINE, EMBASE, and Cochrane Library databases were searched from 1980 through to 2005 using variations on the search terms: melanoma, clinical trial, random, temozolomide, temodal, and temodar.
  • A second phase III study comparing single-agent temozolomide with temozolomide combined with interferon-alpha indicated a significantly higher response rate for the combination treatment arm, but no difference in overall survival was noted.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Melanoma / secondary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914081.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 36
  •  go-up   go-down


59. Inoue T, Kobayashi K, Sawada M, Ishizaki S, Ito H, Fujibayashi M, Tanaka M: Dermoscopic Features of Pigmented Bowen's Disease in a Japanese Female Mimicking Malignant Melanoma. Dermatol Res Pract; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic Features of Pigmented Bowen's Disease in a Japanese Female Mimicking Malignant Melanoma.
  • A 79-year-old Japanese woman presented with a 3-year history of brown-black macule on her right upper arm without symptom.
  • We suspected pigmented skin lesions including seborrheic keratosis, pigmented eccrine poroma, and malignant melanoma and excised completely with a 5 mm margin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811602.001).
  • [ISSN] 1687-6113
  • [Journal-full-title] Dermatology research and practice
  • [ISO-abbreviation] Dermatol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2929512
  •  go-up   go-down


60. Reichle A, Vogt T, Coras B, Terheyden P, Neuber K, Trefzer U, Schultz E, Berand A, Bröcker EB, Landthaler M, Andreesen R: Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res; 2007 Dec;17(6):360-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial.
  • A randomized multi-institutional phase II trial was designed to select metronomic chemotherapy (arm A: trofosfamide 50 mg orally three times daily, day 1+) or combined anti-inflammatory/angiostatic treatment (arm B: trofosfamide as above mentioned plus rofecoxib 25 mg orally, day 1+, and pioglitazone 60 mg orally, day 1+) for further evaluation.
  • A total of 76 patients, mostly (>60%) refractory to at least one previous chemotherapy with maximum tolerated doses, and progression of metastatic melanoma were included.
  • WHO grade 3 (no grade 4) toxicities were reported in arm A/B in 19 and 28%, respectively.
  • In conclusion, control of tumour-associated inflammatory processes (C-reactive protein response) is associated with longer PFS than achieved with metronomic chemotherapy alone in metastatic melanoma.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide / analogs & derivatives. Lactones / therapeutic use. Melanoma / drug therapy. Sulfones / therapeutic use. Thiazolidinediones / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. PIOGLITAZONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992118.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Lactones; 0 / Sulfones; 0 / Thiazolidinediones; 0QTW8Z7MCR / rofecoxib; 8N3DW7272P / Cyclophosphamide; 9007-41-4 / C-Reactive Protein; H64JRU6GJ0 / trofosfamide; X4OV71U42S / pioglitazone
  •  go-up   go-down


61. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL: Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res; 2009 Nov 15;15(22):7029-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine.
  • We sought to assess the effect of the addition of granulocyte/macrophage colony-stimulating factor (GM-CSF) to vaccination with a melanoma vaccine.
  • EXPERIMENTAL DESIGN: Ninety-seven patients with resected melanoma (stage II-IV) were enrolled, stratified by stage, and randomized to receive a cellular melanoma vaccine with or without GM-CSF.
  • The primary endpoint was delayed-type hypersensitivity (DTH) response to melanoma cells.
  • RESULTS: The GM-CSF arm showed enhanced antibody responses with an increase in IgM titer against the TA90 antigen and increased TA90 immune complexes.
  • This arm also had diminished antimelanoma cell delayed-type hypersensitivity response.
  • Peripheral blood leukocyte profiles showed increases in eosinophils and basophils with decreased monocytes in the GM-CSF arm.
  • These immune changes were accompanied by an increase in early melanoma deaths and a trend toward worse survival with GM-CSF.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 1996 Jul-Aug;46(4):225-44 [8673695.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):54-62 [8690525.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):291-7 [10344219.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):720-31 [15613691.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3015-24 [16116189.001]
  • [Cites] Cancer Immunol Immunother. 2006 Mar;55(3):237-45 [16047143.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):215-22 [17200357.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):226-32 [17116643.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):203-14 [17541944.001]
  • [Cites] Eur J Haematol. 2007 Oct;79(4):292-6 [17655695.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jan;58(1):49-59 [18446337.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3239-46 [10866317.001]
  • [Cites] Am J Nephrol. 2000 Jan-Feb;20(1):53-6 [10644869.001]
  • [Cites] J Immunother. 2000 Mar-Apr;23(2):275-81 [10746554.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1614-21 [10764421.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4169-80 [12377960.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4549-54 [12454111.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):186-200 [12491520.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):367-73 [12843799.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2447-56 [12855617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8874-9 [12847287.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4016-26 [14581425.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):64-72 [14593498.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6337-43 [15342423.001]
  • [Cites] J Immunol. 1988 Dec 1;141(11):3882-8 [3141506.001]
  • [Cites] Cancer Immunol Immunother. 1989;29(4):247-54 [2752392.001]
  • [Cites] Blood. 1991 Mar 15;77(6):1131-45 [2001448.001]
  • [Cites] Blood. 1991 Aug 1;78(3):609-15 [1830497.001]
  • [Cites] J Clin Lab Anal. 1992;6(5):329-36 [1403355.001]
  • [Cites] Ann Surg. 1992 Oct;216(4):463-82 [1417196.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Mar;37(3):512-22 [8460920.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):853-7 [7509778.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2913-20 [9738558.001]
  • (PMID = 19903777.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA012582; United States / NCI NIH HHS / CA / R01 CA076489-05; United States / NCI NIH HHS / CA / CA12582; United States / NCI NIH HHS / CA / CA87071; United States / NCI NIH HHS / CA / CA076489-05; United States / NCI NIH HHS / CA / P01 CA012582-35; United States / NCI NIH HHS / CA / K08 CA087071; United States / NCI NIH HHS / CA / CA76489; United States / NCI NIH HHS / CA / R01 CA076489
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS219270; NLM/ PMC2920049
  •  go-up   go-down


62. Thomas JM: Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. J Plast Reconstr Aesthet Surg; 2009 Apr;62(4):442-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma.
  • The first Multicenter Selective Lymphadenectomy Trial (MSLT-I) was designed to test for a survival difference following wide excision of primary melanoma between patients randomised to sentinel lymph node biopsy (SLNB) and early lymphadenectomy when metastatic disease was identified (the biopsy arm) versus observation alone and delayed lymphadenectomy when regional lymph nodes became palpable (the observation arm).
  • Contrary to that stated in the protocol, almost half the patients entered to the observation arm of MSLT-I were investigated by lymphoscintigraphy and regular targeted high-resolution ultrasound which detected nodal metastasis in some patients before it became palpable, thus influencing the primary end-point of the trial.
  • Patients with melanoma die of distant metastatic spread and currently there is no evidence that the SLNB procedure influences distant disease-free survival.
  • [MeSH-major] Lymph Node Excision. Melanoma / secondary. Melanoma / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246272.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 13
  •  go-up   go-down


63. Mocellin S, Pasquali S, Rossi CR, Nitti D: Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst; 2010 Apr 7;102(7):493-501
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
  • BACKGROUND: Based on previous meta-analyses of randomized controlled trials (RCTs), the use of interferon alpha (IFN-alpha) in the adjuvant setting improves disease-free survival (DFS) in patients with high-risk cutaneous melanoma.
  • METHODS: We conducted a systematic review and meta-analysis to examine the effect of IFN-alpha on DFS and OS in patients with high-risk cutaneous melanoma.
  • RESULTS: The meta-analysis included 14 RCTs, published between 1990 and 2008, and involved 8122 patients, of which 4362 patients were allocated to the IFN-alpha arm.
  • CONCLUSION: In patients with high-risk cutaneous melanoma, IFN-alpha adjuvant treatment showed statistically significant improvement in both DFS and OS.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy


64. Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, Pyrhönen S, Seppä H, Korpela M, Kellokumpu-Lehtinen P: Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res; 2005 Aug;15(4):291-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
  • This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma.
  • The response rates were 8% (2/25) in arm A, 13% (4/31) in arm B, 12% (3/25) in arm C and 24% (6/25) in arm D.
  • There were no significant differences in survival (arm A, 11.1 months; arm B, 9.8 months; arm C, 9.1 months; arm D, 7.5 months; P=0.62).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon Type I / therapeutic use. Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034308.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon Type I; 0 / Interferon-alpha; 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; BOLD protocol
  •  go-up   go-down


65. Moschos SJ, Odoux C, Land SR, Agarwala S, Friedland D, Volker KM, Sidor C, Wong M, Kirkwood JM: Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res; 2007 Jun;17(3):193-200
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
  • In patients with stage IIB-III disease, adjuvant high-dose interferon-alpha2b has shown clinical benefit, although metastatic melanoma is currently without any known survival-prolonging therapy.
  • Angiogenesis has been considered important in melanoma progression, and endostatin is an angiogenesis inhibitor with antitumor activity that has shown promising results in murine model systems, prompting investigation of a formulation of rh-Endostatin (EntreMed, Rockville, Maryland, USA) alone and with interferon in metastatic melanoma.
  • Patients were randomly assigned to receive interferon alpha2b (Schering-Plough) 10 million units/m(2) subcutaneously three times a week plus rh-Endostatin 45 mg/m(2) subcutaneously every 12 h (arm A) vs. rh-Endostatin alone (arm B).
  • Basic fibroblast growth factor levels in urine were significantly lower following treatment in patients on arm B (P=0.043).
  • Low titer (<or=1:25) IgG antibodies against the rh-Endo formulation were detected in two patients (one per arm) in cycle 4.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505265.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / P30 CA4790413
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


66. Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, Marshall E, Wagner S: Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer; 2009 Sep 1;115(17):3944-54
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
  • BACKGROUND: The primary objective of this phase 2 study was to assess the objective response rate (complete response [CR] + partial responses [PR]), by Response Evaluation Criteria in Solid Tumors, of PF-3512676, a CpG oligodeoxynucleotide, alone in 2 doses or in combination with dacarbazine (DTIC) in patients with unresectable stage IIIB/C or stage IV malignant melanoma, with the aim of selecting an arm to take forward to a phase 3 portion of the study.
  • RESULTS: The objective response rate (PR or CR, confirmed or unconfirmed) in the 40 mg + DTIC arm was 16% (7 patients) compared with 8% (3 patients) with DTIC alone.
  • Best response of CR or PR or stable disease (SD), with no minimum duration defined for SD, was achieved by 15 (33%) patients in the 40 mg + DTIC arm, 15 (38%) patients in the DTIC-only arm, 8 (17%) patients in the 10-mg arm, and 9 (20%) patients in the 40-mg arm.
  • [MeSH-major] Dacarbazine / administration & dosage. Melanoma / drug therapy. Oligodeoxyribonucleotides / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536884.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Oligodeoxyribonucleotides; 0 / ProMune; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


67. Yoshida Y, Takahashi A, Koga M, Koga K, Kubota Y, Nakayama J: Case of metastatic melanoma in an epitrochlear lymph node arising in a pregnant woman. J Dermatol; 2007 Jan;34(1):48-51
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of metastatic melanoma in an epitrochlear lymph node arising in a pregnant woman.
  • We describe a rare case of metastatic melanoma in an epitrochlear lymph node in a 29-year-old female patient.
  • Histological examination revealed a malignant melanoma.
  • We emphasize that it is important for clinicians to pay attention to the possibility of epitrochlear node metastasis in patients with malignant melanoma in the upper extremity and that it is necessary to perform sentinel node biopsy to identify uncommon lymph node metastasis.
  • [MeSH-major] Melanoma / secondary. Pregnancy Complications, Neoplastic. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Arm. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Pregnancy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204101.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Roberts CE, Harris PA, Thomas JM: Melanoma recurrence confined to a free flap after isolated limb perfusion. J Plast Reconstr Aesthet Surg; 2009 Aug;62(8):e277-9
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma recurrence confined to a free flap after isolated limb perfusion.
  • We present the case of a 72-year-old female presenting to our unit with locally recurrent malignant melanoma of the lower limb almost entirely confined to a fasciocutaneous free flap.
  • The flap (lateral arm donor site) had been used several years previously to reconstruct a wide local excision defect following the excision of recurrent disease.
  • [MeSH-major] Leg / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology. Surgical Flaps / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18463014.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


69. Olsen CM, Zens MS, Stukel TA, Sacerdote C, Chang YM, Armstrong BK, Bataille V, Berwick M, Elwood JM, Holly EA, Kirkpatrick C, Mack T, Bishop JN, Østerlind A, Swerdlow AJ, Zanetti R, Green AC, Karagas MR, Whiteman DC: Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer; 2009 Feb 15;124(4):937-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis.
  • A "divergent pathway" model for the development of cutaneous melanoma has been proposed.
  • We conducted a collaborative analysis to test this hypothesis using the original data from 10 case-control studies of melanoma in women (2,406 cases and 3,119 controls), with assessment of the potential confounding effects of socioeconomic, pigmentary and sun exposure-related factors.
  • Higher nevus count on the arm was associated specifically with an increased risk of melanoma of the trunk (p for trend = 0.0004) and limbs (both upper and lower limb p for trends = 0.01), but not of the head and neck (p for trend = 0.25).
  • The pooled odds ratios for the highest quartile of nonzero nevus count versus none were 4.6 (95% confidence interval (CI) 2.7-7.6) for melanoma of the trunk, 2.0 (95% CI 0.9-4.5) for the head and neck, 4.2 (95% CI 2.3-7.5) for the upper limbs and 3.4 (95% CI 1.5-7.9) for the lower limbs.
  • Aggregate data from these studies suggest that high nevus counts are strongly associated with melanoma of the trunk but less so if at all of the head and neck.
  • This finding supports different etiologic pathways of melanoma development by anatomic site.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / epidemiology. Nevus, Pigmented / diagnosis. Nevus, Pigmented / epidemiology. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Skin Neoplasms / diagnosis. Skin Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):231-5 [9219825.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Jun 14;292(6535):1555-9 [3087514.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):8-12 [9724086.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):276-80 [9766557.001]
  • [Cites] Int J Epidemiol. 1998 Oct;27(5):751-7 [9839729.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):627-32 [10699940.001]
  • [Cites] Int J Epidemiol. 2000 Jun;29(3):416-23 [10869312.001]
  • [Cites] J Am Acad Dermatol. 1999 Apr;40(4):549-57 [10188672.001]
  • [Cites] Br J Dermatol. 1999 Mar;140(3):457-62 [10233266.001]
  • [Cites] Am J Hum Genet. 1999 Aug;65(2):483-92 [10417291.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2003-5 [15598754.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1241-4 [15894679.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):486-93 [15900597.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Melanoma Res. 2006 Apr;16(2):175-82 [16567973.001]
  • [Cites] J Invest Dermatol. 2006 Sep;126(9):2106-10 [16645584.001]
  • [Cites] Cancer Causes Control. 2007 Jun;18(5):485-91 [17450418.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):991-7 [17507627.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1100-8 [17990316.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1340-2 [18408748.001]
  • [Cites] Cancer Causes Control. 2000 Sep;11(8):741-50 [11065011.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):69-82 [11227927.001]
  • [Cites] Stat Med. 2001 Jul 30;20(14):2115-30 [11439425.001]
  • [Cites] J Invest Dermatol. 2001 Aug;117(2):348-52 [11511314.001]
  • [Cites] Nature. 2001 Sep 20;413(6853):271-2 [11565020.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1085-92 [11953854.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):367-75 [12637916.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 4;95(11):806-12 [12783935.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1765-70 [14578177.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90 [14679157.001]
  • [Cites] Br J Dermatol. 1988 May;118(5):641-4 [3395562.001]
  • [Cites] Int J Cancer. 1988 Dec 15;42(6):821-4 [3192324.001]
  • [Cites] Pigment Cell Res. 1988;1(6):397-401 [3237607.001]
  • [Cites] J Invest Dermatol. 1989 Apr;92(4):561-4 [2703724.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 21;81(12):948-52 [2733040.001]
  • [Cites] Int J Epidemiol. 1990 Dec;19(4):801-10 [2084006.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):920-6 [1607409.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):232-6 [8425760.001]
  • [Cites] Am J Epidemiol. 1994 May 1;139(9):869-80 [8166137.001]
  • [Cites] Am J Epidemiol. 1995 May 15;141(10):943-50 [7741124.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):367-76 [7635560.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):377-81 [7635561.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):393-7 [7635564.001]
  • [Cites] J Am Acad Dermatol. 1995 Dec;33(6):923-36; quiz 937-40 [7490362.001]
  • [Cites] J Am Acad Dermatol. 1995 Dec;33(6):1000-7 [7490345.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1605-11 [8664138.001]
  • [Cites] Int J Cancer. 1996 Sep 4;67(5):636-43 [8782651.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):423-8 [15009725.001]
  • [Cites] Br J Cancer. 1977 Dec;36(6):804-9 [597478.001]
  • [Cites] J Natl Cancer Inst. 1984 Feb;72(2):257-66 [6582314.001]
  • [Cites] Med J Aust. 1985 Apr 15;142(8):446-8 [3982348.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):843-8 [9714052.001]
  • (PMID = 19035450.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23927; United States / NIEHS NIH HHS / ES / P30 ES007048; United Kingdom / Cancer Research UK / / A4994; United States / NCI NIH HHS / CA / R03 CA132188-02; United Kingdom / Cancer Research UK / / C588; United States / NCI NIH HHS / CA / P01-CA42101; United States / NCI NIH HHS / CA / R01-CA34382; United States / NIEHS NIH HHS / ES / 5P30ES07048; United States / NCI NIH HHS / CA / CA132188; United Kingdom / Cancer Research UK / / 10589; United States / NCI NIH HHS / CN / N01 CN005230; United States / NCI NIH HHS / CA / CA32262; United Kingdom / Cancer Research UK / / C569/A5030; United States / NCI NIH HHS / CA / R03 CA132188
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS98767; NLM/ PMC2729286
  •  go-up   go-down


70. Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ, Morton DL, MSLT Cooperative Group: The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol; 2010 Dec;17(12):3324-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).
  • BACKGROUND: Complete lymph node dissection, the current standard treatment for nodal metastasis in melanoma, carries the risk of significant morbidity.
  • MATERIALS AND METHODS: The Multicenter Selective Lymphadenectomy Trial I randomized patients to wide excision of a primary melanoma with or without sentinel lymph node biopsy.
  • Immediate completion lymph node dissection (early CLND) was performed when indicated in the SLN arm, while therapeutic dissection (delayed CLND) was performed at the time of clinical recurrence in the wide excision-alone arm.
  • RESULTS: Early CLND was performed in 225 patients, and in the wide excision-alone arm 132 have undergone delayed CLND.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):339-51 [12229941.001]
  • [Cites] Ann Surg Oncol. 2010 Mar;17(3):731-7 [20183910.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):676-80 [12839853.001]
  • [Cites] Tumori. 1984 Dec 31;70(6):529-33 [6531796.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] Am J Surg. 1992 Nov;164(5):462-5; discussion 465-6 [1443370.001]
  • [Cites] Ann Surg Oncol. 1999 Apr-May;6(3):255-62 [10340884.001]
  • [Cites] Arch Surg. 2005 Jan;140(1):85-9 [15655211.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):302-11; discussion 311-3 [16135917.001]
  • [Cites] J Surg Oncol. 2006 Feb 1;93(2):87-91 [16425311.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1307-17 [17005948.001]
  • [Cites] Surgery. 2007 Jun;141(6):728-35 [17560249.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3530-5 [18640934.001]
  • [Cites] Acta Chir Belg. 2008 Nov-Dec;108(6):685-90 [19241918.001]
  • [Cites] Cancer Control. 2009 Jul;16(3):240-7 [19556964.001]
  • [Cites] Ann Surg Oncol. 2009 Oct;16(10):2840-7 [19639366.001]
  • [CommentIn] Ann Surg Oncol. 2011 Feb;18(2):306-8 [21161723.001]
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S311; author reply S312-4 [21773841.001]
  • (PMID = 20614193.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA029605-29; United States / NCI NIH HHS / CA / P01 CA029605; United States / NCI NIH HHS / CA / CA29605; United States / NCI NIH HHS / CA / P01 CA029605-29
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS216768; NLM/ PMC2970739
  •  go-up   go-down


71. Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A: Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol; 2009 Jun 20;27(18):2916-23
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
  • PURPOSE: Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side effects, which necessitates evaluation of health-related quality of life (HRQOL).
  • Our trial examined the HRQOL effects of adjuvant pegylated IFN-alpha-2b (PEG-IFN-alpha-2b) versus observation in patients with stage III melanoma.
  • METHODS: A total of 1,256 patients with stage III melanoma were randomly assigned after full lymphadenectomy to receive either observation (n = 629) or PEG-IFN-alpha-2b (n = 627): induction 6 micrograms/kg/wk [DOSAGE ERROR CORRECTED] for 8 weeks then maintenance 3 micrograms/kg/wk [DOSAGE ERROR CORRECTED] for an intended total duration of 5 years.
  • RESULTS: At 3.8 years of median follow-up, for the primary end point, recurrence-free survival (RFS), risk was reduced by 18% (hazard rate = 0.82; P = .01) in the PEG-IFN-alpha-2b arm compared with observation.
  • Significant and clinically meaningful differences occurred with the PEG-IFN-alpha-2b treatment arm compared with the observation group, showing decreased global HRQOL at month 3 (-11.6 points; 99% CI, -8.2 to -15.0) and year 2 (-10.5 points; 99% CI, -6.6 to -14.4).
  • From a clinical point of view, important differences were found for five scales: two functioning scales (social and role functioning) and three symptom scales (appetite loss, fatigue, and dyspnea), with the PEG-IFN-alpha-2b arm being most impaired.
  • [MeSH-major] Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Jan 10;28(2):e15-6; author reply e17-8 [19949007.001]
  • [CommentIn] J Clin Oncol. 2009 Jun 20;27(18):2896-7 [19433677.001]
  • [ErratumIn] J Clin Oncol. 2009 Sep 20;27(27):4630. Dosage error in published abstract; MEDLINE/PubMed abstract corrected
  • (PMID = 19433686.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


72. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C: Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother; 2009 Jun;32(5):498-507
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
  • We injected intradermally protamine-stabilized mRNAs coding for Melan-A, Tyrosinase, gp100, Mage-A1, Mage-A3, and Survivin in 21 metastatic melanoma patients.
  • During treatment the frequency of Foxp3+/CD4+ regulatory T cells was significantly decreased upon mRNA vaccination in peripheral blood of the patients in the KLH arm, whereas myeloid suppressor cells (CD11b+HLA-DR lo monocytes) were reduced in the patients not receiving KLH.
  • [MeSH-major] Antigens, Neoplasm / genetics. Antigens, Neoplasm / immunology. Bone Neoplasms / immunology. Bone Neoplasms / therapy. Cancer Vaccines. Immunotherapy, Active. Lung Neoplasms / immunology. Lung Neoplasms / therapy. Melanoma / immunology. Melanoma / therapy. Myeloid Cells / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / immunology. T-Lymphocytes, Regulatory / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD11b. Antigens, CD4. Cell Proliferation. Feasibility Studies. Female. Forkhead Transcription Factors. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. HLA-DR Antigens. Hemocyanin / metabolism. Humans. Injections, Intradermal. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Staging. Protamines / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Messenger / therapeutic use. Remission Induction

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609242.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00204607
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Antigens, CD4; 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / HLA-DR Antigens; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / PRM1 protein, human; 0 / Protamines; 0 / RNA, Messenger; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9013-72-3 / Hemocyanin; FV4Y0JO2CX / keyhole-limpet hemocyanin
  •  go-up   go-down


73. Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM: Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol; 2005 Sep 20;23(27):6747-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
  • BACKGROUND: Based on phase II trial results, chemoimmunotherapy combinations have become the preferred treatment for patients with metastatic melanoma in many institutions.
  • This study was performed to determine whether interleukin-2 (IL-2) as a component of chemoimmunotherapy influences survival of patients with metastatic melanoma.
  • PATIENTS AND METHODS: Patients with advanced metastatic melanoma were randomly assigned to receive dacarbazine 250 mg/m2 and cisplatin 30 mg/m2 on days 1 to 3 combined with interferon-alfa-2b 10 x 10(6) U/m2 subcutaneously on days 1 through 5 without (arm A) or with (arm B) a high-dose intravenous decrescendo regimen of IL-2 on days 5 through 10 (18 x 10(6) U/m2/6 hours, 18 x 10(6) U/m2/12 hours, 18 x 10(6) U/m2/24 hours, and 4.5 x 10(6) U/m2 for 3 x 24 hours).
  • RESULTS: Three hundred sixty-three patients with advanced metastatic melanoma were accrued.
  • CONCLUSION: Despite its activity in melanoma as a single agent or in combination with interferon-alfa-2b, the chosen schedule of IL-2 added to the chemoimmunotherapy combination had no clinically relevant activity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Melanoma / mortality. Skin Neoplasms / drug therapy. Skin Neoplasms / mortality. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170182.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-25; United States / NCI NIH HHS / CA / 5U10 CA11488-32
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


74. Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol; 2006 Dec;124(12):1684-93
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28.
  • OBJECTIVES: To report refined rates of death and related outcomes by treatment arm through 12 years after primary treatment of choroidal melanoma and to evaluate characteristics of patients and tumors as predictors of relative treatment effectiveness and time to death.
  • DESIGN: Randomized multicenter clinical trial of iodine 125 ((125)I) brachytherapy vs enucleation conducted as part of the Collaborative Ocular Melanoma Study.
  • Decedents were classified by the independent Mortality Coding Committee as having histopathologically confirmed melanoma metastasis, suspected melanoma metastasis without histopathologic confirmation, another cancer but not melanoma metastasis, or no malignancy.
  • MAIN OUTCOME MEASURES: Deaths from all causes and deaths with histopathologically confirmed melanoma metastasis.
  • For patients in both treatment arms, 5- and 10-year all-cause mortality rates were 19% and 35%, respectively; by 12 years, cumulative all-cause mortality was 43% among patients in the (125)I brachytherapy arm and 41% among those in the enucleation arm.
  • Five-, 10-, and 12-year rates of death with histopathologically confirmed melanoma metastasis were 10%, 18%, and 21%, respectively, in the (125)I brachytherapy arm and 11%, 17%, and 17%, respectively, in the enucleation arm.
  • Older age and larger maximum basal tumor diameter were the primary predictors of time to death from all causes and death with melanoma metastasis.
  • APPLICATION TO CLINICAL PRACTICE: Estimated mortality rates by baseline characteristics should facilitate counseling of patients who have choroidal melanoma of a size and in a location suitable for enucleation or (125)I brachytherapy and no evidence of metastasis or another malignancy.
  • [MeSH-major] Brachytherapy / methods. Choroid Neoplasms / mortality. Choroid Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Melanoma / mortality. Melanoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17159027.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00000124
  • [Grant] United States / NEI NIH HHS / EY / EY06253; United States / NEI NIH HHS / EY / EY06257; United States / NEI NIH HHS / EY / EY06258; United States / NEI NIH HHS / EY / EY06260; United States / NEI NIH HHS / EY / EY06264; United States / NEI NIH HHS / EY / EY06265; United States / NEI NIH HHS / EY / EY06266; United States / NEI NIH HHS / EY / EY06268; United States / NEI NIH HHS / EY / EY06269; United States / NEI NIH HHS / EY / EY06270; United States / NEI NIH HHS / EY / EY06274; United States / NEI NIH HHS / EY / EY06275; United States / NEI NIH HHS / EY / EY06276; United States / NEI NIH HHS / EY / EY06279; United States / NEI NIH HHS / EY / EY06280; United States / NEI NIH HHS / EY / EY06282; United States / NEI NIH HHS / EY / EY06283; United States / NEI NIH HHS / EY / EY06284; United States / NEI NIH HHS / EY / EY06287; United States / NEI NIH HHS / EY / EY06288; United States / NEI NIH HHS / EY / EY06289; United States / NEI NIH HHS / EY / EY06291; United States / NEI NIH HHS / EY / EY06839; United States / NEI NIH HHS / EY / EY06843; United States / NEI NIH HHS / EY / EY06844; United States / NEI NIH HHS / EY / EY06848; United States / NEI NIH HHS / EY / EY06858; United States / NEI NIH HHS / EY / EY06899
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


75. Dewan M, Malatani TS, Ansari MA: Lessons to be learned: a case study approach. Malignant melanoma of soft tissue. J R Soc Promot Health; 2005 Jan;125(1):42-6
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons to be learned: a case study approach. Malignant melanoma of soft tissue.
  • Malignant melanoma of soft tissue, also called clear cell sarcoma (CCS) of tendons and aponeuroses, presents as a soft tissue mass, usually in the lower extremity of young females.
  • Because of the presence of melanin, melanosomes, S-100 protein and the tendency for regional nodal metastases, it has been suggested that this entity be considered a melanoma rather than a soft tissue sarcoma.
  • Such genetic studies need to be performed on primary and metastatic cutaneous, mucosal or ocular melanomas prior to considering them specific for malignant melanoma of soft tissue/CCS.
  • Pleomorphism may or may not be present; the cytoplasm is clear due to the presence of glycogen but, occasionally, the cytoplasm is more eosinophilic, resembling a melanoma.
  • [MeSH-major] Melanoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, Neoplasm. Arm / pathology. DNA-Binding Proteins / analysis. Female. Humans. Immunohistochemistry. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor. Neoplasm Metastasis. Neoplasm Proteins / analysis. S100 Proteins / analysis. Thumb / pathology. Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15712852.001).
  • [ISSN] 1466-4240
  • [Journal-full-title] The journal of the Royal Society for the Promotion of Health
  • [ISO-abbreviation] J R Soc Promot Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / MITF protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / Transcription Factors
  •  go-up   go-down


76. Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, Wolchok JD: Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res; 2010 Aug 01;16(15):4057-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
  • EXPERIMENTAL DESIGN: Human leukocyte antigen (HLA)-A*0201(+) disease-free melanoma patients were randomized to the PMED or i.m. arm, receiving eight vaccinations over 4 months.
  • RESULTS: Twenty-seven patients with stage IIB-IV melanoma were analyzable for immune response.
  • Overall, vaccination induced a response in 30% of patients, which was not significantly associated with study arm or clinical outcome.
  • [MeSH-major] Biolistics. Cancer Vaccines / administration & dosage. Cancer Vaccines / immunology. Melanoma / therapy. Membrane Glycoproteins / administration & dosage
  • [MeSH-minor] Administration, Intranasal. Adult. Aged. Animals. Antigens, Heterophile / administration & dosage. Antigens, Heterophile / adverse effects. CD8-Positive T-Lymphocytes / immunology. DNA / administration & dosage. DNA / adverse effects. DNA / immunology. Female. HLA-A Antigens. HLA-A2 Antigen. Humans. Kaplan-Meier Estimate. Male. Mice. Middle Aged. Neoplasm Staging. Peptides. Pilot Projects. Vaccines, DNA / administration & dosage. Vaccines, DNA / adverse effects. Vaccines, DNA / immunology. gp100 Melanoma Antigen

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7412-20 [19934295.001]
  • [Cites] Clin Plast Surg. 2010 Jan;37(1):127-46 [19914464.001]
  • [Cites] Cytokines Cell Mol Ther. 1999 Dec;5(4):217-25 [10850386.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] J Surg Res. 2002 Feb;102(2):137-43 [11796010.001]
  • [Cites] Vaccine. 2003 Sep 8;21(25-26):4036-42 [12922140.001]
  • [Cites] Nature. 1992 Mar 12;356(6365):152-4 [1545867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4455-9 [8506285.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):459-65 [7543139.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1553-61 [9802967.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5813-20 [10229815.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8114-21 [16299244.001]
  • [Cites] Cancer Immun. 2006;6:8 [16626110.001]
  • [Cites] Vaccine. 2006 May 22;24(21):4582-5 [16188351.001]
  • [Cites] Cytotherapy. 2006;8(5):498-508 [17050255.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):95-106 [17251916.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):540-9 [17255276.001]
  • [Cites] Int Immunol. 2007 Oct;19(10):1223-34 [17898045.001]
  • [Cites] Mol Ther. 2007 Nov;15(11):2044-50 [17726460.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:2-9 [19001145.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:10-5 [19001146.001]
  • [Cites] Mol Ther. 2008 Dec;16(12):2022-9 [18797450.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5950-6 [19018089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1075-81 [19139427.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2130-9 [19276258.001]
  • [Cites] Cancer Immun. 2009;9:5 [19496531.001]
  • [Cites] Vaccine. 2009 Sep 4;27(40):5450-9 [19622402.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5591-8 [19671877.001]
  • [Cites] Clin Cancer Res. 2009 Nov 15;15(22):6881-90 [19903784.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1717-22 [10587362.001]
  • (PMID = 20647477.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCI NIH HHS / CA / P01CA33049
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Heterophile; 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / Peptides; 0 / Si protein, mouse; 0 / Vaccines, DNA; 0 / gp100 Melanoma Antigen; 0 / gp100(280-288) melanoma antigen peptide; 9007-49-2 / DNA
  • [Other-IDs] NLM/ NIHMS215758; NLM/ PMC4241567
  •  go-up   go-down


77. Punt CJ, Suciu S, Gore MA, Koller J, Kruit WH, Thomas J, Patel P, Lienard D, Eggermont AM, Keilholz U: Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. Eur J Cancer; 2006 Nov;42(17):2991-5
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
  • BACKGROUND: Chemoimmunotherapy for patients with metastatic melanoma is associated with high toxicity, and only a subset of patients will benefit.
  • PATIENTS AND METHODS: Patients with metastatic melanoma were randomised to either receive chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha and interleukin-2 (arm A) or initial treatment with two cycles of dacarbazine monotherapy followed irrespective of response by the same 4-drug regimen of chemoimmunotherapy (arm B).
  • Disease stabilisation (complete/partial response or stable disease) was achieved in 19 patients (42.2%) in arm A and 9 patients (20.5%) in arm B.
  • In arm B 32 of the 44 patients continued chemoimmunotherapy after two cycles of dacarbazine.
  • Of 20 patients with progressive disease (PD) after two cycles of dacarbazine in arm B, only 2 patients achieved an objective response.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / therapeutic use. Immunotherapy / methods. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023156.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


78. Chiarion-Sileni V, Del Bianco P, Romanini A, Guida M, Paccagnella A, Dalla Palma M, Naglieri E, Ridolfi R, Silvestri B, Michiara M, De Salvo GL: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]. BMC Cancer; 2006;6:44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
  • BACKGROUND: High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA.
  • In the late nineties, the Italian Melanoma Inter-group started a spontaneous randomized clinical trial (RCT) to verify if a more intense, but shorter than the ECOG 1684 regimen, could improve survival without increasing the toxicity profile.
  • METHODS: Stage III melanoma patients were randomized to receive IFNalfa-2b 20 MU/m2/d intravenously (IV) 5 days/week x 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25 to 28 (Dose-Dense/Dose-Intense, DD/DI, arm), or IFNalfa-2b 20 MU/m2/d IV 5 days/week x 4 weeks followed by 10 MU/m2 subcutaneously (SC) three times per week x 48 weeks (High Dose Interferon, HDI, arm).
  • RESULTS: The most common toxicities in both arms were flu-like and gastrointestinal symptoms, leukopenia, liver and neuro-psychiatric morbidities; with regard to severe toxicity, only leukopenia was statistically more frequent in DD/DI arm than in HDI arm (24% vs 9%) (p = 0.0074), yet, this did not cause an increase in the infection risk.
  • Discontinuation of treatment, due to toxicity, was observed in 13 and 17% of the patients in the DD/DI and HDI arm, respectively.
  • The median actual dose intensity delivered in the DD/DI arm (36.4 MU/m2/week) was statistically higher than that delivered in the HDI arm (30.7 MU/m2/week) (p = 0.003).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 1994 Aug;29(4):514-7 [7951865.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 May;91(5):995-1002 [7515124.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2666-73 [8874325.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):518-24 [15659497.001]
  • [Cites] Melanoma Res. 2000 Feb;10(1):81-92 [10711644.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2444-58 [10856105.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1430-6 [11230488.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2370-80 [11331315.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Eur J Haematol. 2001 Nov-Dec;67(5-6):318-21 [11872080.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Apr;26(4):405-8 [12070414.001]
  • [Cites] Oncology (Williston Park). 2002 Sep;16(9):1177-87; discussion 1190-2, 1197 [12380946.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):7-10 [14665612.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1935-7 [2230885.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1993 Oct;31(10):1308-12 [8271666.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):7-17 [8558223.001]
  • (PMID = 16504154.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN75125874
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC1421423
  •  go-up   go-down


79. Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL: Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res; 2006 Apr 15;12(8):2526-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
  • PURPOSE: Two clinical trials were conducted to evaluate the clinical efficacy and immunologic impact of vaccination against the tyrosinase protein plus systemic interleukin 2 (IL-2) administration in patients with advanced metastatic melanoma.
  • EXPERIMENTAL DESIGN: Full-length tyrosinase was employed as an immunogen to induce diverse immunologic responses against a commonly expressed melanoma antigen.
  • Heterologous prime/boost vaccination with recombinant vaccinia and fowlpox vectors encoding tyrosinase was first explored in a randomized three-arm phase II trial, in which vaccines were administered alone or concurrently with low-dose or high-dose IL-2.
  • CONCLUSIONS: Whereas prime/boost immunization with recombinant vaccinia and fowlpox viruses enhanced antityrosinase immunity in some patients with metastatic melanoma, it was ineffective alone in mediating clinical benefit, and in combination with IL-2 did not mediate clinical benefit significantly different from that expected from treatment with IL-2 alone.
  • [MeSH-major] Cancer Vaccines / immunology. DNA, Recombinant / immunology. Immunization, Secondary / methods. Interleukin-2 / therapeutic use. Melanoma / therapy. Vaccination / methods

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3124-6 [8205528.001]
  • [Cites] Eur J Immunol. 1994 Mar;24(3):759-64 [8125142.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4685-92 [7722321.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1343-8 [7543520.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8125-9 [7667256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Eur J Immunol. 1996 Jan;26(1):224-30 [8566071.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):1965-71 [8642306.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):54-62 [8690525.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8 [8876137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11349-53 [8876138.001]
  • [Cites] Curr Opin Immunol. 1996 Oct;8(5):628-36 [8902387.001]
  • [Cites] Vaccine. 1997 Apr-May;15(6-7):759-68 [9178479.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1595-601 [9362157.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):296-301 [9443408.001]
  • [Cites] J Immunother. 1998 Jan;21(1):27-31 [9456433.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2099-106 [9498746.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6985-92 [9862734.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4446-8 [15483013.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4474-85 [15542798.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1218-27 [15718319.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6043-53 [16087944.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):755-9 [10597191.001]
  • [Cites] Vaccine. 2000 Apr 3;18(19):2015-22 [10706963.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1336-44 [10944556.001]
  • [Cites] Cancer. 2000 Aug 25;90(4):252-7 [10966567.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3964-73 [11099326.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1848-54 [11251017.001]
  • [Cites] J Immunother. 2001 May-Jun;24(3):212-20 [11394498.001]
  • [Cites] Eur J Immunol. 2001 Sep;31(9):2690-701 [11536167.001]
  • [Cites] Clin J Oncol Nurs. 2001 Sep-Oct;5(5):207-17 [11905416.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):967-72 [12006508.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Immunol Methods. 2002 Aug 1;266(1-2):87-103 [12133625.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 [12427970.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):188-94 [12569574.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2973-80 [12912944.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1595-9 [14996715.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2122-32 [15169798.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3989-96 [15459222.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5 [2679456.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4651-7 [7722317.001]
  • (PMID = 16638862.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010763-01; United States / Intramural NIH HHS / / Z01 SC003811-32; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / DNA, Recombinant; 0 / Immunoglobulin G; 0 / Interleukin-2; 0 / RNA, Messenger; 82115-62-6 / Interferon-gamma; EC 1.14.18.1 / Monophenol Monooxygenase
  • [Other-IDs] NLM/ NIHMS35505; NLM/ PMC2151202
  •  go-up   go-down


80. Wong SF, Jakowatz JG, Taheri R: Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma. Clin Ther; 2005 Dec;27(12):1942-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
  • BACKGROUND: In the United States, patients with high-risk stage II or III melanoma are often treated with adjuvant interferon (IFN) therapy for 1 year after surgery.
  • OBJECTIVE: The aim of this report was to describe a potential drug-drug interaction between IFN alfa-2b and gemfibrozil in a patient with malignant melanoma.
  • METHODS: This report presents the case of a 43-year-old male patient weighing 101 kg with newly diagnosed stage III melanoma of the left arm, with metastasis to the supraclavicular node.
  • The patient presented to the University of California Irvine Medical Center, Orange, California with severe gastrointestinal (GI) symptoms and elevated hepatic enzyme concentrations at week 48 of 104 of adjuvant treatment of malignant melanoma (IFN alfa 11 MU SC TIW in combination with the investigational melanoma vaccine melanoma theraccine 1.25 mL [I mL lysate + 0.25 mL vaccine adjuvant] given SC at weeks 1, 2, 3, 4, 8, 16, 24, 32, 40, and 48 and then every 8 weeks until week 104), and IFN-induced hypertriglyceridemia (gemfibrozil 600 mg PO BID).
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / adverse effects. Drug Interactions. Humans. Lymphatic Metastasis. Male. Melanoma / drug therapy. Recombinant Proteins. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Triglycerides.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gemfibrozil .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507380.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypolipidemic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b; Q8X02027X3 / Gemfibrozil
  •  go-up   go-down


81. Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS, Formisano B, Cascinelli N: Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol; 2006 Apr;17(4):571-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
  • BACKGROUND: The addition of cytokines to chemotherapy (CT) has obtained encouraging but contradictory results in metastatic melanoma.
  • PATIENTS AND METHODS: A total of 151 untreated metastatic melanoma patients were randomized, 75 on arm A (cisplatin 30 mg/m2 on days 1-3, vindesine 2.5 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 1-3), and 76 on arm B (same CVD scheme plus interferon-alpha2b on days 1-5 and interleukin-2 on days 1-5 and 8-15, both administered subcutaneously), either recycled every 3 weeks.
  • We observed a response rate (RR) of 21% on arm A versus 33% on arm B; three patients (4%) given bioCT had complete responses (CRs).
  • Median time to progression (TTP) was identical; median overall survival (OS) time was 12 months on arm A and 11 months on arm B.
  • Therefore, bioCT cannot be recommended as standard first-line therapy for metastatic melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16469753.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


82. Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM: Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother; 2008 Oct;31(8):781-91
Hazardous Substances Data Bank. D-MANNITOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
  • Here, we report the results of a pilot trial designed to study the immunogenicity of the analog peptide NY-ESO-1 157-165V in combination with CpG 7909/PF3512676 and Montanide ISA 720 in patients with stage III/IV NY-ESO-1-expressing melanoma.
  • Eight patients were immunized either with Montanide and CpG (arm 1, 3 patients); Montanide and peptide NY-ESO-1 157-165V (arm 2, 2 patients); or with Montanide, CpG, and peptide NY-ESO-1 157-165V (arm 3, 3 patients).
  • Only the 3 patients immunized with Montanide, CpG, and peptide NY-ESO-1 157-165V in arm 3 developed a rapid increase of effector-memory NY-ESO-1-specific CD8+ T cells, detectable ex vivo.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1998 Jan 19;187(2):265-70 [9432985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1757-64 [10359579.001]
  • [Cites] J Immunother. 2004 Nov-Dec;27(6):472-7 [15534491.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):739-46 [15696196.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1243-55 [15837811.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):252-7 [15838382.001]
  • [Cites] PLoS Med. 2004 Nov;1(2):e28 [15578105.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1912-6 [16488988.001]
  • [Cites] Annu Rev Immunol. 2006;24:175-208 [16551247.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2326s-2330s [16609053.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):317-27 [16482562.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4112-9 [17371966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52 [17517626.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):2042-8 [17640060.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4499-506 [10969798.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):948-55 [10878370.001]
  • [Cites] Int Immunol. 1999 Dec;11(12):1971-80 [10590263.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4946-52 [10987311.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):740-5 [11130078.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):766s-772s [11300471.001]
  • [Cites] Annu Rev Immunol. 2002;20:709-60 [11861616.001]
  • [Cites] Nat Med. 2002 Apr;8(4):379-85 [11927944.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):1822-9 [12574347.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1140-5 [14871849.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Eur J Immunol. 1992 May;22(5):1261-9 [1533591.001]
  • [Cites] J Invest Dermatol. 1996 Jul;107(1):63-7 [8752841.001]
  • [Cites] J Immunol. 1996 Sep 15;157(6):2539-48 [8805655.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1349-54 [9547346.001]
  • (PMID = 18779741.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112198; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCRR NIH HHS / RR / UL1 RR024153; United States / NCI NIH HHS / CA / R01 CA090360; United States / NCI NIH HHS / CA / R01 CA090360-05S1; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCI NIH HHS / CA / R01 CA112198-01; United States / NCI NIH HHS / CA / P50 CA121973; United States / NCI NIH HHS / CA / R01 CA112198-02; United States / NCI NIH HHS / CA / R01 CA090360-04; United States / NCI NIH HHS / CA / R01 CA090360-01A2; United States / NCRR NIH HHS / RR / M01 RR000056-441011; United States / NCI NIH HHS / CA / R01 CA090360-02; United States / NCI NIH HHS / CA / R01 CA112198-04; United States / NCI NIH HHS / CA / R01 CA112198-03; United States / NCI NIH HHS / CA / R01 CA090360-05; United States / NCI NIH HHS / CA / R01 CA090360-03; United States / NCI NIH HHS / CA / CA90360; United States / NCRR NIH HHS / RR / M01 RR000056-36; United States / NCRR NIH HHS / RR / UL1 RR024153-01; United States / NCI NIH HHS / CA / R01 CA112198
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Neoplasm Proteins; 0 / Oleic Acids; 0 / Oligodeoxyribonucleotides; 0 / Peptide Fragments; 0 / ProMune; 0 / peptide NY-ESO-1 157-165; 25339-93-9 / mannide monooleate; 3OWL53L36A / Mannitol
  • [Other-IDs] NLM/ NIHMS84664; NLM/ PMC3901357
  •  go-up   go-down


83. Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, Segal E, Nayler O, Clozel M: A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs; 2007 Jun;25(3):247-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
  • There is no effective systemic therapy for disseminated metastatic melanoma.
  • Data suggest that endothelin may play a role in pathophysiology of melanoma and that the dual endothelin receptor antagonist bosentan may have anti-tumor activity.
  • This multicenter, open-label, single-arm, prospective, proof-of-concept study assessed the effects of bosentan monotherapy (500 mg oral tablets, bid) on tumor response in patients with stage IV metastatic melanoma.
  • Among the 35 patients included in this study with stage IV metastatic melanoma, 21 (60%) were stage M1C, 10 (29%) stage M1B and 4 (11%) stage M1A (American Joint Committee on Cancer [AJCC] classification).
  • Nine patients (26%) had received prior therapy for stage IV melanoma.
  • Bosentan might have benefit in disease stabilization in certain patients with metastatic melanoma and deserves further investigation in combination with other anticancer drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endothelin Receptor Antagonists. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2004 Dec;123(6):1135-9 [15610525.001]
  • [Cites] J Card Fail. 2005 Feb;11(1):12-20 [15704058.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):748-59 [14662431.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1118-25 [15020614.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):443-52 [12189238.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):32-7 [7615973.001]
  • [Cites] Hum Mol Genet. 1995 Nov;4(11):2089-96 [8589685.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1436-43 [14973117.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3892-7 [8632985.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1267-76 [8001159.001]
  • [Cites] Eur Heart J. 2004 Dec;25(24):2243-78 [15589643.001]
  • [Cites] Int J Cancer. 2000 Apr 15;86(2):182-7 [10738244.001]
  • [Cites] Virchows Arch. 2001 May;438(5):485-91 [11407477.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1277-85 [8001160.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1681-9 [11092528.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] J Vasc Res. 2001 Nov-Dec;38(6):536-45 [11740152.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jun;231(6):1111-9 [16741059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11496-500 [10500205.001]
  • (PMID = 17021960.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endothelin Receptor Antagonists; 0 / RNA, Messenger; 0 / Receptors, Endothelin; 0 / Sulfonamides; 0 / Tablets; Q326023R30 / bosentan
  •  go-up   go-down


84. Damato EM, Damato B, Sibbring JS, Coupland SE: Ciliary body melanoma with partial deletion of chromosome 3 detected with multiplex ligation-dependent probe amplification. Graefes Arch Clin Exp Ophthalmol; 2008 Nov;246(11):1637-40
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliary body melanoma with partial deletion of chromosome 3 detected with multiplex ligation-dependent probe amplification.
  • We report a case of ciliary body melanoma with partial deletion of chromosome 3, which was missed with fluorescence in situ hybridization (FISH) but detected with multiplex ligation-dependent probe amplification (MLPA).
  • RESULTS: Histology showed the tumour to a melanoma of mixed cell type.
  • FISH with a centromeric probe indicated that the tumour was of disomy 3 type with a good prognosis; however, MLPA revealed a partial deletion of the long arm of chromosome 3.
  • To our knowledge this is the first reported case of ciliary body melanoma assessed by MLPA.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 3. Ciliary Body. Melanoma / genetics. Uveal Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):9-16 [15714058.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Apr;6(4):493-506 [16613538.001]
  • [Cites] Ophthalmology. 2007 Oct;114(10):1925-31 [17719643.001]
  • (PMID = 18563430.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


85. Elias EG, Zapas JL, Beam SL, Brown SD: GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial. Oncology (Williston Park); 2005 Apr;19(4 Suppl 2):15-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.
  • Cytokines have been used in the treatment of patients with cutaneous melanoma.
  • In this open-label, single-arm study of 16 high-risk patients, we combined these two agents to take advantage of their different but complementary functions.
  • In addition, patients who had large tumors that could yield over 100 million live tumor cells received autologous melanoma vaccines.
  • The combination treatment regimen of GM-CSF and IL-2 with or without autologous vaccine used adjuvantly appears to benefit high-risk melanoma patients; further clinical testing of this regimen is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Immunotherapy / methods. Interleukin-2 / administration & dosage. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934495.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Recombinant Proteins; 123774-72-1 / sargramostim; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


86. Stadler R, Luger T, Bieber T, Köhler U, Linse R, Technau K, Schubert R, Schroth K, Vakilzadeh F, Volkenandt M, Gollnick H, Von Eick H, Thoren F, Strannegård O: Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. Acta Oncol; 2006;45(4):389-99
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
  • In a prospective, controlled, randomised, multicentre study 252 patients with totally resected cutaneous melanoma (248 in stage II-III and 4 in stage IV) were either treated with two doses of dacarbazine (DTIC) followed by a 6-month treatment with 3 MU thrice weekly of highly purified natural interferon-alpha (n = 128; arm A) or received no adjuvant treatment (n = 124; arm B).
  • After a median follow-up of 8.5 years ITT analysis showed that the difference in survival was statistically significant with respect to melanoma-related deaths (HR = 0.65, CI = 0.46-0.97, p = 0.022) and close to significance with respect to overall survival (HR 0.71, CI 0.49-1.00, p = 0.052).
  • The risk reduction of melanoma-associated death, calculated by Cox proportional hazards modelling, after adjusting for identified predictive variables, was almost 50% (p = 0.002).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / mortality. Skin Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Oncol. 2006;45(4):369-72 [16760171.001]
  • (PMID = 16760174.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Interferon-alpha; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


87. Rodriguez T, Méndez R, Roberts CH, Ruiz-Cabello F, Dodi IA, López Nevot MA, Paco L, Maleno I, Marsh SG, Pawelec G, Garrido F: High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol Immunother; 2005 Feb;54(2):141-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
  • The goal of our study was to explore HLA genotyping and phenotyping in a variety of melanoma tumour cell lines.
  • A total of 91 melanoma cell lines were characterised for HLA class I and II genotype.
  • Unexpectedly, we found that 19.7% of the melanoma cell lines were homozygous for HLA class I genotypes, sometimes associated with HLA class II homozygosity (8.79%) and sometimes not (10.98%).
  • To identify the reasons underlying the high frequency of HLA homozygosity we searched for genomic deletions using eight pairs of highly polymorphic microsatellite markers covering the entire extended HLA complex on the short arm of chromosome 6.
  • Our results were compatible with hemizygous deletions and suggest that loss of heterozygosity on chromosome arm 6p is a common feature in melanoma cell lines.
  • These results led us to conclude that loss of heterozygosity in chromosome 6 is nonrandom and is possibly an immunologically relevant event in human malignant melanoma.
  • [MeSH-major] Chromosomes, Human, Pair 6 / genetics. Gene Expression Regulation, Neoplastic. Genes, MHC Class I / genetics. Genes, MHC Class II / genetics. Loss of Heterozygosity. Melanoma / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592718.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


88. Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis NE, Schuster R, Siehl JM, Foerster MH, Thiel E, Keilholz U: A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol; 2006 Dec;17(12):1826-9
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with proven metastatic uveal melanoma were randomly assigned to receive 1000 mg/m(2) of gemcitabine plus 3500 mg/m(2) of treosulfan (GeT) or 3500 mg/m(2) of T.
  • Seven confirmed stable diseases (SDs) and one partial remission (PR) were observed in 24 patients treated with the GeT regimen, whereas no PR and only three SDs were observed in the T arm (P = 0.08).
  • Median progression-free survival (PFS) was 3 months (95% CI 1.1-4.9) and 2 months (95% CI 1.7-2.3) in the GeT and T arm (P = 0.008, log-rank).
  • Six and 12 months PFS was 34.8% and 17.9% and 16.7% and 0% always favoring the GeT arm.
  • CONCLUSIONS: This first randomized trial in metastatic uveal melanoma showed a superior PFS and a trend for a higher response/stabilization rate of the GeT combination over T.

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TREOSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971664.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; CO61ER3EPI / treosulfan; G1LN9045DK / Busulfan
  •  go-up   go-down


89. Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D: Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res; 2008 Aug;18(4):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
  • Systemic treatment of metastatic melanoma is of low efficacy, and new therapeutic strategies are needed.
  • This study was aimed to evaluate the efficacy, safety, and pharmacokinetics of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate (MS-275) in patients with pretreated metastatic melanoma.
  • Patients with unresectable AJCC stage IV melanoma refractory to at least one earlier systemic therapy were randomized to receive MS-275 3 mg biweekly (days 1+15, arm A) or 7 mg weekly (days 1+8+15, arm B), in 4-week cycles.
  • On the basis of Simon's two-stage design, the study initially allowed an entry of 14 patients per arm; if there was at least one responder, additional 33 patients were to be enrolled.
  • Four (29%) patients in arm A and three (21%) patients in arm B showed disease stabilizations.
  • Single-agent treatment with MS-275 was well-tolerated and showed long-term tumor stabilizations, but no objective responses in pretreated metastatic melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzamides / therapeutic use. Histone Deacetylase Inhibitors. Melanoma / drug therapy. Pyridines / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18626312.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Pyridines; 1ZNY4FKK9H / entinostat; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


90. Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P, Morosini P, Perrone T, Bajetta E, Anichini A: Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res; 2010 Dec 1;16(23):5862-72
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
  • PURPOSE: To assess the clinical and biological activity of the association of bevacizumab and fotemustine as first-line treatment in advanced melanoma patients.
  • EXPERIMENTAL DESIGN: Previously untreated, metastatic melanoma patients (n = 20) received bevacizumab (at 15 mg/kg every 3 weeks) and fotemustine (100 mg/m² by intravenous administration on days 1, 8, and 15, repeated after 4 weeks) in a multicenter, single-arm, open-label, phase II study.
  • Effects of fotemustine on melanoma cells, in vitro, on vascular endothelial growth factor (VEGF)-C release and apoptosis were assessed by ELISA and flow cytometry, respectively.
  • In vitro, fotemustine inhibited VEGF-C release by melanoma cells without inducing significant cell death.
  • CONCLUSIONS: The combination of bevacizumab plus fotemustine has clinical activity in advanced melanoma and promotes systemic modulation of angiogenesis and lymphangiogenesis factors.
  • [MeSH-major] Angiogenic Proteins / blood. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphangiogenesis. Melanoma / drug therapy. Nitrosourea Compounds / administration & dosage. Organophosphorus Compounds / administration & dosage. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [ErratumIn] Clin Cancer Res. 2011 Feb 1;17(3):630
  • (PMID = 21030496.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01069627
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 2S9ZZM9Q9V / Bevacizumab; GQ7JL9P5I2 / fotemustine
  •  go-up   go-down


91. Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, Volkenandt M, Grabbe S, Proske U, Schadendorf D, Brockmeyer N, Vogt T, Rompel R, Kaufmann R, Kaatz M, Näher H, Mohr P, Eigentler T, Livingstone E, Garbe C: Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J Clin Oncol; 2009 Jul 20;27(21):3496-502
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
  • PURPOSE Interferon alfa (IFN-alpha) has shown clinical efficacy in the adjuvant treatment of patients with high-risk melanoma in several clinical trials, but optimal dosing and duration of treatment are still under discussion.
  • PATIENTS AND METHODS In an attempt to investigate the potential role of a modified high-dose induction phase, lymph node-negative patients with resected primary malignant melanoma of more than 1.5-mm tumor thickness were included in this prospective randomized multicenter Dermatologic Cooperative Oncology Group trial.
  • This schedule consisted of 5 times weekly 10 MU/m(2) IFN-alpha-2b IV for 2 weeks and 5 times weekly 10 MU/m(2) IFN-alpha-2b administered subcutaneously (SC) for another 2 weeks followed by 23 months of low-dose IFN-alpha-2b (LDI) 3 MU SC three times a week (arm A).
  • LDI 3 MU three times a week was given for 24 months in arm B.
  • Five-year relapse-free survival rates were 68.0% (arm A) and 67.1% (arm B), respectively.
  • Likewise, melanoma-related fatalities were similar between both groups, resulting in 5-year overall survival rates of 80.2% (arm A) and 82.9% (arm B).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interferon-alpha / administration & dosage. Melanoma. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433681.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


92. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, Wu H, Lesinski GB, Kendra K, Chen HX, Walker MJ, Carson WE 3rd: A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol; 2007 Aug;14(8):2367-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
  • BACKGROUND: Vascular endothelial growth factor (VEGF) is a proangiogenic molecule produced by melanoma cells.
  • We hypothesized that administration of bevacizumab (Bev), a monoclonal antibody that neutralizes VEGF, with low-dose interferon alfa-2b (IFN-alpha2b), an inhibitor of basic fibroblast growth factor (FGF), would lead to the regression of metastatic melanoma.
  • METHODS: Patients with metastatic melanoma were randomized to receive Bev (15 mg/kg intravenously every 2 weeks) with or without low-dose IFN-alpha2b (1 MU/m2 subcutaneously daily).
  • RESULTS: Thirty-two patients (16 per arm) were accrued (18 male, 14 female; mean age 57.5 years).
  • One patient (Bev plus IFN-alpha2b arm) had locally recurrent scalp disease that partially responded to therapy.
  • CONCLUSIONS: Bev was well tolerated at this dose and prolonged disease stabilization was achieved in one-quarter of metastatic melanoma patients.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534686.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95426; United States / NCI NIH HHS / CA / K24 CA93670; United States / NCI NIH HHS / CA / P01 CA95426; United States / NCI NIH HHS / CA / P30 CA16058-28; United States / NCI NIH HHS / CA / T32 CA09338-27; United States / NCI NIH HHS / CA / U01 CA-076576-06
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 2S9ZZM9Q9V / Bevacizumab; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


93. Schadendorf D, Hauschild A, Ugurel S, Thoelke A, Egberts F, Kreissig M, Linse R, Trefzer U, Vogt T, Tilgen W, Mohr P, Garbe C: Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol; 2006 Oct;17(10):1592-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
  • BACKGROUND: Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours.
  • The purpose of this study was to test a dose-intensified regimen of temozolomide in melanoma patients with brain metastases in a prospective, open-label, multicentre phase II trial.
  • PATIENTS AND METHODS: Forty-five patients with asymptomatic brain metastases from melanoma were stratified into arm A (no prior chemotherapy; n = 21) and arm B (previous chemotherapy; n = 24).
  • Patients received oral temozolomide either 150 mg/m(2)/day (arm A) or 125 mg/m(2)/day (arm B), days 1-7 and 15-21, every 28 days.
  • RESULTS: Two patients (4.4%) achieved a partial response (PR) in brain metastases (one in each arm), one of them (2.2%) also showing a PR in extracerebral disease.
  • An additional five patients (11.1%; two in arm A, three in arm B) showed disease stabilisation (SD) in brain and other sites.
  • Median survival time from therapy onset was 3.5 months (range 0.7-8.3; arm B) and 4.3 months (range 1.6-11.8; arm A), P = 0.43.
  • CONCLUSIONS: Oral administration of temozolomide given bi-weekly is well-tolerated in melanoma patients with cerebral involvement.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005632.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


94. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol; 2008 May 1;26(13):2178-85
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
  • PURPOSE: This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma.
  • PATIENTS AND METHODS: This randomized, double-blind, placebo-controlled, multicenter study enrolled chemotherapy-naive patients with stage III (unresectable) or IV melanoma.
  • RESULTS: Median PFS in the sorafenib plus dacarbazine arm was 21.1 weeks versus 11.7 weeks in the placebo plus dacarbazine arm (hazard ratio [HR], 0.665; P = .068).
  • There were statistically significant improvements in PFS rates at 6 and 9 months, and in TTP (median, 21.1 v 11.7 weeks; HR, 0.619) in favor of the sorafenib plus dacarbazine arm.
  • CONCLUSION: Sorafenib plus dacarbazine was well tolerated in patients with advanced melanoma and yielded an encouraging improvement in PFS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445842.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 7GR28W0FJI / Dacarbazine; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


95. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H: Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2005 Jun;16(6):950-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
  • We designed a randomized phase II study to evaluate and compare the activity and safety profile of the combination versus single-agent TMZ in patients with advanced melanoma.
  • RESULTS: Tumor responses (complete and partial responses) were seen in 16 patients (26%) in arm A and 19 patients (29%) in arm B.
  • The median time to progression (TTP) was 3.8 months in arm A and 5.8 months in arm B.
  • The median overall survival (OS) was 11.5 months in arm A and 12 months in arm B.
  • There was significantly more grade 3 and 4 emesis in the combination arm.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829494.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


96. Girardi S, Gaudy C, Gouvernet J, Teston J, Richard MA, Grob JJ: Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: a randomized study. Int J Cancer; 2006 May 1;118(9):2276-80
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: a randomized study.
  • Most education campaigns for melanoma (MM) detection in the general population have used the "ABCD" algorithm, although recognition of objects in the real life is based on a holistic image recognition rather than on analytic criteria.
  • A prospective 4-arm stratified randomized trial in 255 individuals compared 3 realistic educative interventions by leaflets:.
  • 1) ABCD algorithm ("ABCD"), 2) a set of photographs chosen to stimulate recognition of MM among benign pigmented lesions ("Cog"), 3) photographs + explanations ("Cog-Ex" arm) and 4) no intervention ("NI").
  • In the "ABCD" arm, sensitivity slightly improved (80 to 83.8%, p = 0.04), but specificity dropped from 65.1 to 56.3% (p < 0.001), with no benefit in accuracy as compared to "NI".
  • In "Cog" arm, there was no change in sensitivity, but a strong increase in specificity (65.9 to 81.1%, p < 0.001) and accuracy (42.1 to 53.1%, p < 0.001).
  • Under stress (T2), there was a dramatic loss of specificity and accuracy in "ABCD" arm (65.1 to 44.1%, p < 0.001 and 40.8% to 35.8%, p < or = 0.001) without higher gain in sensitivity, while sensitivity and accuracy increased (p < 0.005) after "Cog" leaflet, without decreasing specificity.
  • [MeSH-major] Cognition. Melanoma / diagnosis. Patient Education as Topic. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16331608.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Ives NJ, Stowe RL, Lorigan P, Wheatley K: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol; 2007 Dec 1;25(34):5426-34
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.
  • PURPOSE: To assess the effect of adding interferon-alpha (IFN) +/- interleukin-2 (IL-2) to chemotherapy in patients with metastatic melanoma.
  • METHODS A published data meta-analysis of trials of biochemotherapy versus chemotherapy in patients with metastatic melanoma was undertaken.
  • The only subgroup analysis performed was by type of immunotherapy, with trials divided according to whether IFN only or IFN and IL-2 were administered in the biochemotherapy arm.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048825.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  •  go-up   go-down


98. van Gils W, Kilic E, Brüggenwirth HT, Vaarwater J, Verbiest MM, Beverloo B, van Til-Berg ME, Paridaens D, Luyten GP, de Klein A: Regional deletion and amplification on chromosome 6 in a uveal melanoma case without abnormalities on chromosomes 1p, 3 and 8. Melanoma Res; 2008 Feb;18(1):10-5
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional deletion and amplification on chromosome 6 in a uveal melanoma case without abnormalities on chromosomes 1p, 3 and 8.
  • Uveal melanoma (UM) is the most common primary intraocular malignancy in adults.
  • Loss of the long arm and gain of the short arm of chromosome 6 are frequently observed chromosomal aberrations in UM, together with loss of chromosome 1p36, loss of chromosome 3 and gain of chromosome 8.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 3 / genetics. Chromosomes, Human, Pair 6 / genetics. Chromosomes, Human, Pair 8 / genetics. Gene Amplification. Melanoma / genetics. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Chromosome 8 Deletion.
  • Genetic Alliance. consumer health - Uveal melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227702.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


99. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L: Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res; 2009 Feb 15;15(4):1443-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
  • PURPOSE: No therapy has ever shown prolongation of survival in stage IV metastatic melanoma.
  • The association of cytokine-induced autoimmunity with improved prognosis led us to investigate the effect of multi-epitope melanoma vaccines alone and in combination with cytokines in this Eastern Cooperative Oncology Group multicenter phase II trial.
  • Peptide vaccine alone (arm A), or combined with granulocyte-monocyte colony-stimulating factor (GM-CSF; Immunex) 250 microg/d subcutaneously for 14 of 28 days each month (arm B), or combined with IFN-alpha2b (Intron A; Schering-Plough) 10 million units/m2 three times a week (arm C), or combined with both IFN-alpha2b and GM-CSF (arm D).
  • Immune responses to at least one melanoma antigen were observed in 26 of 75 (35%) patients with serial samples.
  • CONCLUSION: Immune response to vaccination correlates with prolonged survival in patients with metastatic melanoma and is not enhanced by immunomodulatory cytokines as tested in this trial.

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4474-85 [15542798.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8456-60 [15548718.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):3080-6 [15728523.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6747-55 [16170182.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8978-91 [16260696.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):9001-7 [16260697.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3164-71 [16809739.001]
  • [Cites] Am J Clin Oncol. 2006 Aug;29(4):352-60 [16891861.001]
  • [Cites] J Immunother. 2006 Nov-Dec;29(6):616-27 [17063124.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2756-65 [10537339.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1603-5 [10764419.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1614-21 [10764421.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2370-80 [11331315.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):703-11 [11340576.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2058-66 [11956266.001]
  • [Cites] Genome Biol. 2002 Jun 25;3(7):RESEARCH0035 [12184809.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3703-18 [12202672.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1101-12 [12209697.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4181-90 [12377961.001]
  • [Cites] Semin Cutan Med Surg. 2003 Mar;22(1):68-75 [12773015.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2342-8 [12805336.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3343-50 [12947071.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4347-55 [14555505.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4016-26 [14581425.001]
  • [Cites] Semin Cancer Biol. 2003 Dec;13(6):401-7 [15001158.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1670-7 [15014018.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702 [15252201.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] N Engl J Med. 1988 Jun 16;318(24):1557-63 [3259674.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] J Exp Med. 1992 Nov 1;176(5):1453-7 [1402688.001]
  • [Cites] Eur J Immunol. 1994 Mar;24(3):759-64 [8125142.001]
  • [Cites] Science. 1994 Apr 29;264(5159):716-9 [7513441.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):347-52 [7516411.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):35-42 [8006593.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458-62 [8022805.001]
  • [Cites] J Exp Med. 1995 Jan 1;181(1):363-8 [7807017.001]
  • [Cites] Nat Med. 1998 Mar;4(3):321-7 [9500606.001]
  • [Cites] Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23 [9815296.001]
  • (PMID = 19228745.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA066636-15; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / CA039229-22; United States / NCI NIH HHS / CA / U10 CA066636; None / None / / U10 CA023318-32; United States / NCI NIH HHS / CA / U10 CA039229; United States / NCI NIH HHS / CA / CA39229; United States / NCI NIH HHS / CA / U10 CA021115-34; None / None / / U10 CA021115-34; United States / NCI NIH HHS / CA / U10 CA023318-32; United States / NCI NIH HHS / CA / U10 CA039229-22; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / CA23318; None / None / / U10 CA066636-15
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Interferon-alpha; 0 / Recombinant Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ NIHMS104522; NLM/ PMC2759898
  •  go-up   go-down


100. Slingluff CL, Petroni GR, Smolkin ME, Chianese-Bullock KA, Smith K, Murphy C, Galeassi N, Neese PY, Grosh WW, Nail CJ, Ross M, von Mehren M, Haas N, Boisvert ME, Kirkwood JM: Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother; 2010 Jul-Aug;33(6):630-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
  • Analyses included 194 patients who received either IFA-AN or IFA-VG for all vaccines, and a subset of 93 patients best matched by study arm for vaccine antigens (12 melanoma peptides restricted by major histocompatibility complex class I, 12MP; plus a tetanus helper peptide, tet) administered with IFA but without granulocyte macrophage-colony stimulating factor.
  • CD8 T-cell response rates to the 12 melanoma peptides were 53% [95% confidence interval (CI), 44%, 61%)] for IFA-AN and 46% [95% CI, 32%, 59%)] for IFA-VG.
  • Despite the necessarily retrospective nature of the analysis and limitations of multiple comparisons, our summary data support the use of IFA-VG as an adjuvant with multipeptide vaccines in melanoma patients.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TALLOW .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3012-24 [11595689.001]
  • [Cites] J Clin Oncol. 2011 Jul 20;29(21):2924-32 [21690475.001]
  • [Cites] J Immunol. 1996 Sep 15;157(6):2539-48 [8805655.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2099-106 [9498746.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4474-85 [15542798.001]
  • [Cites] Cancer Immunol Immunother. 2005 Apr;54(4):359-71 [15378283.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):3080-6 [15728523.001]
  • [Cites] J Immunother. 2006 Mar-Apr;29(2):224-31 [16531823.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6386-95 [17975151.001]
  • [Cites] J Immunother. 2008 May;31(4):420-30 [18391753.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4973-80 [18809608.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3538-49 [18923873.001]
  • [Cites] Vaccine. 2009 Mar 10;27(11):1764-70 [19185050.001]
  • [Cites] Clin Cancer Res. 2009 Nov 15;15(22):7036-44 [19903780.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4016-26 [14581425.001]
  • (PMID = 20551833.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / R01 CA118386-05; United States / NCI NIH HHS / CA / NIH R01 CA118386; United States / NCI NIH HHS / CA / R21 CA103528-01; United States / NCI NIH HHS / CA / P30 CA044579; United States / NCRR NIH HHS / RR / NIH M01 RR00847; United States / NCI NIH HHS / CA / R01 CA118386-02; United States / NCI NIH HHS / CA / R21 CA103528-02; United States / NCI NIH HHS / CA / P30 CA044579-18; United States / NCI NIH HHS / CA / R01 CA118386-03; United States / NCI NIH HHS / CA / NIH R21 CA103528; United States / NCI NIH HHS / CA / R01 CA118386; United States / NCI NIH HHS / CA / R21 CA103528; United States / NCI NIH HHS / CA / R01 CA118386-04; United States / NCI NIH HHS / CA / NIH/NCI P30 CA44579; United States / NCRR NIH HHS / RR / M01 RR000847
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Fats; 0 / Peptide Fragments; 0 / Vaccines, Subunit; 61789-97-7 / tallow; 9007-81-2 / Freund's Adjuvant
  • [Other-IDs] NLM/ NIHMS221635; NLM/ PMC3218563
  •  go-up   go-down






Advertisement